<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Adv</journal-id><journal-id journal-id-type="iso-abbrev">Sci Adv</journal-id><journal-id journal-id-type="publisher-id">sciadv</journal-id><journal-id journal-id-type="hwp">advances</journal-id><journal-title-group><journal-title>Science Advances</journal-title></journal-title-group><issn pub-type="epub">2375-2548</issn><publisher><publisher-name>American Association for the Advancement of Science</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40397745</article-id><article-id pub-id-type="pmc">PMC12094228</article-id><article-id pub-id-type="publisher-id">ads5002</article-id><article-id pub-id-type="doi">10.1126/sciadv.ads5002</article-id><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biomedicine and Life Sciences</subject></subj-group><subj-group subj-group-type="legacy-article-type"><subject>SciAdv r-articles</subject></subj-group><subj-group subj-group-type="field"><subject>Cancer</subject><subject>Health and Medicine</subject></subj-group><subj-group subj-group-type="overline"><subject>Health and Medicine</subject></subj-group></article-categories><title-group><article-title>Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer</article-title><alt-title alt-title-type="short">cfDNA fragmentomes for monitoring of patients with pancreatic cancer</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9882-040X</contrib-id><name><surname>Hruban</surname><given-names>Carolyn</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8436-501X</contrib-id><name><surname>Bruhm</surname><given-names>Daniel C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2891-0762</contrib-id><name><surname>Chen</surname><given-names>Inna M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="afn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9690-7349</contrib-id><name><surname>Koul</surname><given-names>Shashikant</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9097-6511</contrib-id><name><surname>Annapragada</surname><given-names>Akshaya V.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1310-0257</contrib-id><name><surname>Vulpescu</surname><given-names>Nicholas A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2319-6360</contrib-id><name><surname>Short</surname><given-names>Sarah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9804-7744</contrib-id><name><surname>Theile</surname><given-names>Susann</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boyapati</surname><given-names>Kavya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8562-8459</contrib-id><name><surname>Alipanahi</surname><given-names>Bahar</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1928-7139</contrib-id><name><surname>Skidmore</surname><given-names>Zachary L.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7967-3213</contrib-id><name><surname>Leal</surname><given-names>Alessandro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cristiano</surname><given-names>Stephen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Adleff</surname><given-names>Vilmos</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4217-6560</contrib-id><name><surname>Johannsen</surname><given-names>Julia S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4702-2656</contrib-id><name><surname>Scharpf</surname><given-names>Robert B.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3591-8482</contrib-id><name><surname>Foda</surname><given-names>Zachariah H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5492-9013</contrib-id><name><surname>Phallen</surname><given-names>Jillian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1195-438X</contrib-id><name><surname>Velculescu</surname><given-names>Victor E.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Visualization" vocab-term-identifier="https://web.archive.org/web/20180313224017/http://dictionary.credit.niso.org/Contributor_Roles/Visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-original-draft/">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/term/contributor-roles/" vocab-term="Writing - review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/term/contributor-roles-writing-review-editing/">Writing - review &#x00026; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label><sup>1</sup></label>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Oncology, Copenhagen University Hospital&#x02013;Herlev and Gentofte, Herlev, Denmark.</aff><aff id="aff3"><label><sup>3</sup></label>Delfi Diagnostics Inc., Baltimore, MD, USA.</aff><aff id="aff4"><label><sup>4</sup></label>Department of Medicine, Copenhagen University Hospital&#x02013;Herlev and Gentofte, Herlev, Denmark.</aff><aff id="aff5"><label><sup>5</sup></label>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</aff><aff id="aff6"><label><sup>6</sup></label>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Email: <email xlink:href="foda@jhmi.edu">foda@jhmi.edu</email> (Z.H.F.); <email xlink:href="jphalle2@jhmi.edu">jphalle2@jhmi.edu</email> (J.P.); <email xlink:href="velculescu@jhmi.edu">velculescu@jhmi.edu</email> (V.E.V.)</corresp><fn id="afn1" fn-type="equal"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="pub"><day>21</day><month>5</month><year>2025</year></pub-date><volume>11</volume><issue>21</issue><elocation-id>eads5002</elocation-id><history>
<date date-type="received"><day>15</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>07</day><month>4</month><year>2025</year></date>
</history><permissions><copyright-statement>Copyright &#x000a9; 2025 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-05-21">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution license</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="sciadv.ads5002.pdf"/><abstract><p>Determining response to therapy for patients with pancreatic cancer can be challenging. We evaluated methods for assessing therapeutic response using cell-free DNA (cfDNA) in plasma from patients with metastatic pancreatic cancer in the CheckPAC trial (NCT02866383). Patients were evaluated before and after initiation of therapy using tumor-informed plasma whole-genome sequencing (WGMAF) and tumor-independent genome-wide cfDNA fragmentation profiles and repeat landscapes (ARTEMIS-DELFI). Using WGMAF, molecular responders had a median overall survival (OS) of 319 days compared to 126 days for nonresponders [hazard ratio (HR)&#x000a0;=&#x000a0;0.29, 95% confidence interval (CI)&#x000a0;=&#x000a0;0.11&#x02013;0.79, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.011]. For ARTEMIS-DELFI, patients with low scores after therapy initiation had longer median OS than patients with high scores (233 versus 172 days, HR&#x000a0;=&#x000a0;0.12, 95% CI&#x000a0;=&#x000a0;0.046&#x02013;0.31, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). We validated ARTEMIS-DELFI in patients with pancreatic cancer in the PACTO trial (NCT02767557). These analyses suggest that noninvasive mutation and fragmentation-based cfDNA approaches can identify therapeutic response of individuals with pancreatic cancer.</p></abstract><abstract abstract-type="teaser"><p>Noninvasive mutation-based and fragmentation-based cfDNA approaches can identify response to therapy in pancreatic cancer.</p></abstract><funding-group><award-group id="award1832426"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA121113</award-id></award-group><award-group id="award1832427"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>1T32GM136577</award-id></award-group><award-group id="award1832428"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA006973</award-id></award-group><award-group id="award1832429"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA233259</award-id></award-group><award-group id="award1832430"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA062924</award-id></award-group><award-group id="award1832431"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA271896</award-id></award-group><award-group id="award1833505"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap>
</funding-source><award-id>CA062924</award-id></award-group><award-group id="award1832432"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001009</institution-id><institution>Bristol-Myers Squibb Foundation</institution></institution-wrap>
</funding-source><award-id>CA209-752</award-id></award-group><award-group id="award1832433"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001009</institution-id><institution>Bristol-Myers Squibb Foundation</institution></institution-wrap>
</funding-source><award-id>AX-CL-PANC-PI-007100</award-id></award-group><award-group id="award1833504"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Delfi Diagnostics</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833493"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005984</institution-id><institution>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833501"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004436</institution-id><institution>Commonwealth Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833499"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>The Honorable Tina Brozman Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833497"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015616</institution-id><institution>Gray Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833495"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>SU2C in-Time Lung Cancer Interception Dream Team Grant</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833492"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005984</institution-id><institution>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833509"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001009</institution-id><institution>Bristol-Myers Squibb Foundation</institution></institution-wrap>
</funding-source><award-id>CA209-752</award-id></award-group><award-group id="award1832425"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009730</institution-id><institution>Stand Up To Cancer</institution></institution-wrap>
</funding-source><award-id>SU2C-AACR-DT1415</award-id></award-group><award-group id="award1833491"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005984</institution-id><institution>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833494"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>SU2C in-Time Lung Cancer Interception Dream Team Grant</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833496"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015616</institution-id><institution>Gray Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833498"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>The Honorable Tina Brozman Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833500"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004436</institution-id><institution>Commonwealth Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833502"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019683</institution-id><institution>Cole Foundation</institution></institution-wrap>
</funding-source></award-group><award-group id="award1833503"><funding-source>
<institution-wrap><institution-id institution-id-type="FundRef"/><institution>Delfi Diagnostics</institution></institution-wrap>
</funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="introduction" disp-level="1"><title>INTRODUCTION</title><p>In 2020, more than 450,000 people are estimated to have died from pancreatic cancer worldwide (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>). Most pancreatic cancers are ductal adenocarcinomas (PDAC), and patients with PDAC have an extremely poor prognosis, especially when their disease is diagnosed at an advanced stage (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>), with a grim 12% survival rate (<xref rid="R3" ref-type="bibr"><italic toggle="yes">3</italic></xref>). For patients with metastatic or locally advanced nonresectable PDAC, the standard-of-care treatment is either chemotherapy or symptomatic management (<xref rid="R4" ref-type="bibr"><italic toggle="yes">4</italic></xref>). Recent studies, however, suggest that some patients with advanced-stage disease respond to targeted therapies based on somatic mutations in their cancers or to immune checkpoint blockade treatment (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>&#x02013;<xref rid="R9" ref-type="bibr"><italic toggle="yes">9</italic></xref>). Unfortunately, determining response early during therapy using currently available imaging techniques is imperfect, especially in small, isoattenuating lesions (<xref rid="R10" ref-type="bibr"><italic toggle="yes">10</italic></xref>). Continuing ineffective therapy can be detrimental as tumors can double in size within 5 months in the absence of therapeutic response (<xref rid="R11" ref-type="bibr"><italic toggle="yes">11</italic></xref>&#x02013;<xref rid="R13" ref-type="bibr"><italic toggle="yes">13</italic></xref>). Consequently, there is a need to develop noninvasive approaches that can provide a real-time and accurate assessment of response to therapy for patients with PDAC.</p><p>Current tools for monitoring PDAC include radiographic Response Evaluation Criteria in Solid Tumors (RECIST 1.1) assessment using computed tomography (CT) and evaluation of serum CA19-9 (<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>). However, each of these methods has shortcomings. CT scans can be misleading in patients treated with immunotherapy as immune infiltration can mask therapeutic response or appear as pseudo-progression in radiographs (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). In addition, not all patients have tumors that secrete CA19-9, such as patients who are Lewis antigen Le(a&#x02212;b&#x02212;), limiting the use of this protein as a biomarker for response to therapy (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>).</p><p>Liquid biopsy approaches based on detection of cell-free DNA (cfDNA) have been developed for both detecting cancer and for monitoring patients with cancer (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>). Mutation-based assays for liquid biopsy including targeted sequencing and droplet digital polymerase chain reaction (PCR) have both been used for longitudinal monitoring of patients with pancreatic cancer (<xref rid="R6" ref-type="bibr"><italic toggle="yes">6</italic></xref>, <xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>). These approaches rely on either known mutations from sequencing the patient-matched tumor or mutations prevalent in the tumor type, such as those at positions of hotspot alterations in <italic toggle="yes">KRAS</italic>. However, not all cancers harbor the hotspot mutations or have an available tumor biopsy that can be assessed by these approaches. In addition, sequence alterations due to white blood cell clonal hematopoesis can confound the ability to determine whether the mutation is tumor derived.</p><p>Whole-genome sequencing (WGS) of cfDNA has been used to identify rearrangements for sensitive cancer detection and monitoring during therapy (<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>). In addition, genome-wide analyses of cfDNA copy number changes have been used in applications for both detection and monitoring (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>, <xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>). Genome-wide analyses of sequence alterations have also been used for disease monitoring when combined with a priori tumor sequencing (<xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>). cfDNA fragmentome approaches such as DNA evaluation of fragments for early interception (DELFI), incorporate cfDNA fragment characteristics from across the genome and have shown promise for early cancer detection (<xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>&#x02013;<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>). The DELFI approach uses low-coverage WGS and does not require a priori information of the somatic mutations in the patient&#x02019;s cancer (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>). Recent studies have demonstrated the utility of fragmentome-based approaches for monitoring disease during therapy by predicting mutant allele fractions (MAFs) and tumor burden through a tumor- and mutation-independent approach (<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>&#x02013;<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). Repeat element landscapes from cfDNA [analysis of repeat elements in disease (ARTEMIS)] have also recently been shown to have utility for detecting and monitoring cancer (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>).</p><p>In this study, we developed and evaluated a tumor-informed [whole-genome MAF (WGMAF)] and a tumor-independent cfDNA approach (ARTEMIS-DELFI) in serial plasma samples from patients in a clinical trial who were treated with late-line immunotherapy combined with radiation therapy for metastatic pancreatic cancer. The results were validated in a separate clinical trial of patients with locally advanced or metastatic pancreatic cancer treated with first-line chemotherapy and were compared to other monitoring modalities, including molecular and imaging results as well as patient outcome.</p></sec><sec sec-type="results" disp-level="1"><title>RESULTS</title><sec disp-level="2"><title>Patient population and approach</title><p>To evaluate methods for noninvasive prediction of survival and response to therapy, we analyzed a cohort of patients with pancreatic cancer, treated with radiation and immune checkpoint blockade, who had longitudinal blood collection in the CheckPAC trial (NCT02866383) (<xref rid="F1" ref-type="fig">Fig. 1A</xref>) (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>). Patients were eligible for the trial if they had unresectable refractory metastatic pancreatic cancer and had completed at least one line of standard-of-care chemotherapy. All patients received stereotactic body radiation therapy of 15&#x000a0;gray to one of their tumor sites and were randomized 1:1 to two arms: either nivolumab alone or nivolumab with ipilimumab. The patients&#x02019; tumors were biopsied before and after radiation, and plasma samples were obtained at regular intervals throughout therapy. A total of 84 patients were enrolled in this trial, of which 43 had tumor tissue or blood samples that were available for molecular analyses (<xref rid="T1" ref-type="table">Table 1</xref> and fig. S1A). Tumors from patients included in our analyses were located in the body, head, tail, and uncinate process of the pancreas with up to five metastatic lesions detected at enrollment. The analyzed patients were diagnosed 4 months to more than 3 years before enrollment and a subset of patients (8 of 43) previously had surgical intervention for their disease. Responses were determined by a combination of clinical assessment and CT imaging using RECIST version 1.1, which compares images from any time point during therapy to baseline images. Patients included in our analyses had nearly equal representation of men and women (22 and 21, respectively), ranging in age from 35 to 75 years, and with most having a positive smoking history (<xref rid="F1" ref-type="fig">Fig. 1B</xref>, <xref rid="T1" ref-type="table">Table 1</xref>, and table S1).</p><fig position="float" id="F1" fig-type="image" specific-use="distribute"><label>Fig. 1.</label><caption><title>Overview of study design and samples.</title><p>(<bold>A</bold>) Schematic of study design showing timeline of treatment, timeline of sample collection, and molecular analyses for both the CheckPAC and the PACTO cohorts. Tumor and WBCs were sequenced from patients in the CheckPAC cohort to generate a list of somatic variants present in tumor. WGMAF values were calculated in plasma samples as the number of mutant observations divided by total number of observations across all mutated positions with tumor-specific somatic mutations. ARTEMIS-DELFI scores were generated with a fixed model using fragmentation patterns, chromosomal gains and losses, and repeat elements as features. These scores were compared to progression-free survival and OS data, and multivariate hazard analyses were performed. (<bold>B</bold>) Description of CheckPAC and PACTO patients at baseline. Categories show the location of tumor, the number of metastatic sites, the time between initial diagnosis and trial enrollment, prior surgery, smoking status, sex, method of assessment of progression, trial arm, and cancer stage.</p></caption><graphic xlink:href="sciadv.ads5002-f1" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1.</label><caption><title>Patient characteristics for CheckPAC and PACTO cohorts.</title></caption><table frame="hsides" rules="groups"><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><col width="%" span="1"/><thead><tr><th rowspan="2" valign="bottom" align="left" scope="rowgroup" colspan="1"> Patient characteristic</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">CheckPAC cohort</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">PACTO cohort</th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Analyzed</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">All</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Analyzed</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">All</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">n</italic>&#x000a0;=&#x000a0;43</bold>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">n</italic>&#x000a0;=&#x000a0;84</bold>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">n</italic>&#x000a0;=&#x000a0;40</bold>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">
<bold><italic toggle="yes">n</italic>&#x000a0;=&#x000a0;147</bold>
</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Age, years</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mean</td><td valign="bottom" align="center" rowspan="1" colspan="1">65</td><td valign="bottom" align="center" rowspan="1" colspan="1">63</td><td valign="bottom" align="center" rowspan="1" colspan="1">65</td><td valign="bottom" align="center" rowspan="1" colspan="1">65</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Range</td><td valign="bottom" align="center" rowspan="1" colspan="1">(35&#x02013;75)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(35&#x02013;80)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(36&#x02013;84)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(36&#x02013;84)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Sex, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">M</td><td valign="bottom" align="center" rowspan="1" colspan="1">22 (51%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">44 (52%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">25 (63%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">86(59%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">F</td><td valign="bottom" align="center" rowspan="1" colspan="1">21 (49%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">40 (48%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">15 (38%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">61 (41%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Time since first diagnosis (days)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mean</td><td valign="bottom" align="center" rowspan="1" colspan="1">476</td><td valign="bottom" align="center" rowspan="1" colspan="1">93</td><td valign="bottom" align="center" rowspan="1" colspan="1">18</td><td valign="bottom" align="center" rowspan="1" colspan="1">25</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Range</td><td valign="bottom" align="center" rowspan="1" colspan="1">(93&#x02013;1433)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(79&#x02013;2072)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(10&#x02013;47)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(7&#x02013;525)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Cancer stage, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">II</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (1%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">III</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (8%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">14 (10%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">IV</td><td valign="bottom" align="center" rowspan="1" colspan="1">43 (100%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">84 (100%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">37 (93%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">129 (88%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Unknown</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (2%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Histology, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Pancreatic ductal adenocarcinoma</td><td valign="bottom" align="center" rowspan="1" colspan="1">41 (95%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">82 (98%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">36 (90%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">134 (91%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mucinous adenocarcinoma</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (8%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (3%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Adenosquamous carcinoma</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (3%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (3%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Unknown</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (2%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (2%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Metastases, number</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mean</td><td valign="bottom" align="center" rowspan="1" colspan="1">2</td><td valign="bottom" align="center" rowspan="1" colspan="1">2</td><td valign="bottom" align="center" rowspan="1" colspan="1">2</td><td valign="bottom" align="center" rowspan="1" colspan="1">2</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Range</td><td valign="bottom" align="center" rowspan="1" colspan="1">(1&#x02013;7)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(1&#x02013;7)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(0&#x02013;5)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(0&#x02013;5)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Location of metastases,<italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Liver</td><td valign="bottom" align="center" rowspan="1" colspan="1">38 (88%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">80 (95%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">36 (90%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">107 (73%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Lung</td><td valign="bottom" align="center" rowspan="1" colspan="1">17 (40%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">26 (31%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">8 (20%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">33 (22%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mediastinal nodes</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (6%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (3%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (11%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Abdominal nodes</td><td valign="bottom" align="center" rowspan="1" colspan="1">14 (33%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">23 (27%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (40%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">51 (35%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Peritoneal</td><td valign="bottom" align="center" rowspan="1" colspan="1">4 (9%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">7 (8%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">12 (30%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">36 (24%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Bone</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">8 (10%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">11 (7%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Retroperitoneal</td><td valign="bottom" align="center" rowspan="1" colspan="1">4 (9%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">15 (18%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (3%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">13 (9%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Ascites</td><td valign="bottom" align="center" rowspan="1" colspan="1">7 (16%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (19%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">12 (8%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Adrenal</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (2%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (3%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (3%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Trial arm, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Nivo</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (37%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">41 (49%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Nivo + ipi</td><td valign="bottom" align="center" rowspan="1" colspan="1">27 (63%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">43 (51%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Chemo</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">20 (50%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">70 (48%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Chemo + IL-6</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">20 (50%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">71 (48%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">N/A</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">6 (4%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Site of radiotherapy, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Liver</td><td valign="bottom" align="center" rowspan="1" colspan="1">34 (79%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">64 (76%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Lung</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (7%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (6%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Abdominal wall</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (2%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (1%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Local recurrence</td><td valign="bottom" align="center" rowspan="1" colspan="1">3 (7%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">9 (11%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Retroperitoneal</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (1%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Other</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">4 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Overall survival, days</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mean</td><td valign="bottom" align="center" rowspan="1" colspan="1">322</td><td valign="bottom" align="center" rowspan="1" colspan="1">215</td><td valign="bottom" align="center" rowspan="1" colspan="1">280</td><td valign="bottom" align="center" rowspan="1" colspan="1">301</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Range</td><td valign="bottom" align="center" rowspan="1" colspan="1">(37&#x02013;2720)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(10&#x02013;2720)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(25&#x02013;1059)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(9&#x02013;1187)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Progression-free survival, days</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Mean</td><td valign="bottom" align="center" rowspan="1" colspan="1">139</td><td valign="bottom" align="center" rowspan="1" colspan="1">91</td><td valign="bottom" align="center" rowspan="1" colspan="1">168</td><td valign="bottom" align="center" rowspan="1" colspan="1">180</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Range</td><td valign="bottom" align="center" rowspan="1" colspan="1">(26&#x02013;1433)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(4&#x02013;1433)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(12&#x02013;678)</td><td valign="bottom" align="center" rowspan="1" colspan="1">(9&#x02013;678)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Best overall response, BOR, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Partial response (PR)</td><td valign="bottom" align="center" rowspan="1" colspan="1">7 (16%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">7 (8%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">14 (35%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">53 (36%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Stable disease (SD)</td><td valign="bottom" align="center" rowspan="1" colspan="1">13 (30%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (19%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">16 (40%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">50 (34%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Progressive disease (PD)</td><td valign="bottom" align="center" rowspan="1" colspan="1">21 (49%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">51 (61%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">6 (15%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">26 (18%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Not evaluable (NE)</td><td valign="bottom" align="center" rowspan="1" colspan="1">2 (5%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">10 (12%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">4 (10%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">18 (12%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Survival status, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Dead</td><td valign="bottom" align="center" rowspan="1" colspan="1">42 (98%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">83 (99%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">40 (100%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">147 (100%)</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">Alive</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (2%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">1 (1%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<bold>Mutations, <italic toggle="yes">n</italic> (%)</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">KRAS</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">26 (60%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">36 (90%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">TP53</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">24 (56%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">32 (80%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">SMAD4</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">4 (9%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="bottom" align="left" rowspan="1" colspan="1">
<italic toggle="yes">CDKN2A</italic>
</td><td valign="bottom" align="center" rowspan="1" colspan="1">5 (12%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td><td valign="bottom" align="center" rowspan="1" colspan="1">6 (15%)</td><td valign="bottom" align="center" rowspan="1" colspan="1">-</td></tr></tbody></table></table-wrap><p>To assess these noninvasive approaches for monitoring in an independent validation study, we analyzed individuals from the PACTO trial (NCT02767557) (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>). Patients were enrolled in the PACTO trial if they had locally advanced or metastatic pancreatic adenocarcinoma and had received no prior antineoplastic chemotherapy or anticancer drugs. Patients were randomized 1:1 to two arms, both of which received gemcitabine/nab-paclitaxel, while one arm also received the IL-6 receptor antibody tocilizumab. Patients from both arms had plasma samples taken at regular intervals throughout therapy. The trial enrolled 147 treatment-na&#x000ef;ve patients with pancreatic cancer, of which a subset of 40 with known ctDNA levels at baseline were included in our analyses (<xref rid="F1" ref-type="fig">Fig. 1A</xref>, <xref rid="T1" ref-type="table">Table 1</xref>, and fig. S1A). The characteristics of the analyzed patients in the PACTO trial were largely similar to those of the CheckPAC trial but had a slightly older age profile, no previous systemic treatment after first PDAC diagnosis, and included three patients with locally advanced but not metastatic disease. (<xref rid="F1" ref-type="fig">Fig. 1B</xref>, <xref rid="T1" ref-type="table">Table 1</xref>, and table S2).</p><p>We assessed whether response to therapy in patients from these trials could be evaluated using both tumor-informed as well as tumor-independent methods for predicting response and survival. We compared these approaches to current methods of measuring response to therapy using standard imaging approaches (RECIST 1.1), as well as the known serum pancreatic cancer biomarker CA19-9. For all the molecular methods, we evaluated blood draws for patients in CheckPAC from the baseline time point (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;35) as well as the second time point at a median of 8 weeks after initiation of therapy (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;33, median&#x000a0;=&#x000a0;54 days, range&#x000a0;=&#x000a0;14 to 114 days) with similar time points evaluated in PACTO. This allowed for a direct comparison to 8-week RECIST 1.1 measurements (median: 49 days, range&#x000a0;=&#x000a0;26 to 60 days) (fig. S2A and table S1). Previous studies have suggested that this time point would be useful to assess for response using liquid biopsy approaches for patients treated with immune checkpoint blockade (<xref rid="R34" ref-type="bibr"><italic toggle="yes">34</italic></xref>, <xref rid="R35" ref-type="bibr"><italic toggle="yes">35</italic></xref>).</p></sec><sec disp-level="2"><title>Tumor-informed WGMAF approach</title><p>We developed a tumor-informed approach (WGMAF) based on WGS of the tumors from these patients (table S3). In this approach, somatic mutations were detected in the tumor using the matched buffy coat (normal) as a filter to select high-quality somatic variants. The tumor-derived somatic mutations from each patient were then evaluated as a set in the cfDNA from that patient&#x02019;s plasma. For every plasma sample, we counted the total number of fragments containing mutations in the set and divided this by the total number of fragments at these locations. This estimate of MAF does not rely on a panel of mutations or known variants and can therefore be optimized for each patient (fig. S3).</p><p>To assess our WGMAF approach for cancer monitoring, we performed WGS using tumor and matched normal samples (target coverage 60 to 100&#x000d7; for tumors and 30 to 60&#x000d7; for normal samples) for all patients where samples were available and where tumors had pathologically assessed neoplastic cellularity &#x0003e;20% (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;37) (fig. S1). Comparison of sequence alterations in the matched tumor and normal samples revealed 9 to 13,432 alterations among these samples as well as one tumor with hypermutator phenotype harboring 44,737 somatic mutations (<xref rid="F2" ref-type="fig">Fig. 2A</xref>, fig. S4, and table S4). Analysis of the somatic alterations revealed that 82% of the tumors sequenced harbored a mutation in the <italic toggle="yes">KRAS</italic> oncogene and 75% harbored a mutation in the <italic toggle="yes">TP53</italic> tumor suppressor gene (<xref rid="T1" ref-type="table">Table 1</xref>, fig. S4, and table S4), both of which are commonly mutated in PDAC (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>). The tumor with a hypermutator phenotype harbored a G440E mutation in <italic toggle="yes">MLH1</italic>, which was classified as a likely pathogenic germline change by InSiGHT and ClinVAR (<xref rid="R37" ref-type="bibr"><italic toggle="yes">37</italic></xref>, <xref rid="R38" ref-type="bibr"><italic toggle="yes">38</italic></xref>), but has only been documented as a somatic change in two cancer samples in the COSMIC database (<xref rid="R39" ref-type="bibr"><italic toggle="yes">39</italic></xref>). None of these patients were found to have mismatch repair deficiency by immunohistochemistry.</p><fig position="float" id="F2" fig-type="image" specific-use="distribute"><label>Fig. 2.</label><caption><title>WGMAF approach predicts survival for patients in CheckPAC trial.</title><p>(<bold>A</bold>) Tree plot showing WGMAF levels at baseline and on-treatment as well as tumor cellularity measurements and clinical response for each patient. The section above the dashed line describes evaluable patients, while the section below the dashed line shows patients who were not evaluable because of unavailable tumor or plasma samples or an insufficient number of somatic mutations found in tumor. The number of somatic mutations identified in tumors are listed to the left of the tree plot in descending order, colored by mutation type. Baseline MAF is plotted on the left side of tree plot, and on-treatment MAF is plotted on the right side. The central spine of the tree plot shows the tumor cellularity using two methods, pathological cellularity evaluated from hematoxylin and eosin sample and cellularity assessed from molecular sequencing data, as well as BOR RECIST for each patient. (<bold>B</bold>) Boxplot of WGMAF values for baseline samples and follow-up samples sorted by clinical PD, SD, and PR. <italic toggle="yes">P</italic> values were calculated using the Wilcoxon signed-rank test. (<bold>C</bold>) Kaplan-Meier survival curves showing progression-free survival probability and OS probability based on the median WGMAF value for CheckPAC patients at the second follow-up (on-treatment) plasma evaluation. Nonresponders were classified as those with WGMAF above median value of 0.87%, while responders were classified as those with WGMAF below 0.87%.</p></caption><graphic xlink:href="sciadv.ads5002-f2" position="float"/></fig><p>The evaluability of patient samples by WGMAF requires a sufficient number of somatic mutations identified in the sequenced tumor to enable detection of ctDNA in plasma even when the tumor fraction in plasma is low. Here, we considered a patient evaluable by this approach if at least 50 mutations were identified in the tumor as the probability of identifying one or more somatic mutation in plasma is 0.75 or higher when the tumor fraction is 1% or higher (table S5). Of the 25 patients who were evaluable by WGMAF, 20 patients had a second blood draw at 8 weeks from treatment initiation, allowing these patients to be examined for both cfDNA and imaging analyses (fig. S2, A and B). To independently determine the accuracy of the WGMAF approach, we compared the WGMAF estimated level of ctDNA for 10 samples using this approach to a targeted sequencing approach of 64 genes for determining the MAF and found that the two methods had a high correlation across a range of MAF values (<italic toggle="yes">R</italic>&#x000a0;=&#x000a0;0.90, Pearson correlation, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, Wilcoxon signed-rank test) (fig. S5).</p><p>As WGMAF was highly correlated with targeted sequencing approaches that directly measure MAF, we next evaluated whether a landmark analysis of WGMAF after therapy was associated with clinical response. We chose to focus on landmark analyses as they have the advantage of being logistically simpler (only a single blood tube is needed), and there is precedent for using landmark measurements for noninvasive determination of therapeutic response (<xref rid="R40" ref-type="bibr"><italic toggle="yes">40</italic></xref>, <xref rid="R41" ref-type="bibr"><italic toggle="yes">41</italic></xref>). While baseline samples of these patients (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;18) typically had relatively high WGMAF scores, with a median value of 4.9% [95% confidence interval (CI)&#x000a0;=&#x000a0;1.9 to 10%] (<xref rid="F2" ref-type="fig">Fig. 2B</xref>), landmark samples at the 8-week time point revealed very low on-treatment WGMAF measurements (median score&#x000a0;=&#x000a0;0.044%, 95% CI&#x000a0;=&#x000a0;0.0048 to 0.53%) for patients who were determined to be partial responders (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;4) from their best overall responses (BORs) by RECIST 1.1, whereas patients with stable disease (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;7) (median score&#x000a0;=&#x000a0;0.84%, 95% CI&#x000a0;=&#x000a0;0.046 to 3.8%) or progressive disease (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;8) (median score&#x000a0;=&#x000a0;8.7%, 95% CI&#x000a0;=&#x000a0;1.34 to 19.4%) had higher WGMAF scores [Wilcoxon signed-rank test <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.004 for PR (partial response) compared to PD (progressive disease), <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.012 for PR compared to SD (stable disease)] (<xref rid="F2" ref-type="fig">Fig. 2, A and B</xref>).</p><p>Using the median on-treatment landmark WGMAF value as a cut point for determining molecular response, we found that of the 20 patients analyzed (fig. S1A), the 10 patients with scores below the cut point identified as molecular responders had a statistically longer progression free survival (PFS) compared to patients with scores above the cut point identified as molecular nonresponders (PFS of 157 days versus 51 days, respectively) [hazard ratio (HR)&#x000a0;=&#x000a0;0.23, 95% CI&#x000a0;=&#x000a0;0.07 to 0.69, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0053, log-rank test]. Similarly, molecular responders had a significantly longer overall survival (OS) compared to molecular nonresponders (OS of 319 days compared to 126 days, respectively (HR&#x000a0;=&#x000a0;0.29, 95% CI&#x000a0;=&#x000a0;0.11 to 0.79, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.011, log-rank test) (<xref rid="F2" ref-type="fig">Fig. 2C</xref>). Among patients with stable disease by imaging at the 8-week time point (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;9) molecular response assessment by WGMAF provided a similar stratification of OS, with molecular responders having a median OS of 332 days compared to 112 days for molecular nonresponders (HR&#x000a0;=&#x000a0;0.16, 95% CI&#x000a0;=&#x000a0;0.02 to 1.16, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0019, log-rank test) (fig. S6).</p><p>To assess whether WGMAF scores are an independent predictor of OS when evaluated together with known clinical risk factors of pancreatic cancer progression, we performed a multivariate analysis with factors known to be associated with outcomes for patients with pancreatic cancer (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>). We included age, Eastern Cooperative Oncology Group performance status (ECOG PS), weight loss, modified Glasgow prognostic score (MGPS), and treatment type, as well as the standardized WGMAF scores before and after treatment initiation. In this multivariate analysis, we found WGMAF scores were the only statistically significant feature associated with patient OS (HR&#x000a0;=&#x000a0;2.38, 95% CI&#x000a0;=&#x000a0;1.20 to 4.73, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.01, Cox proportional hazards) (fig. S7).</p></sec><sec disp-level="2"><title>Genome-wide cfDNA fragmentation analyses</title><p>We next evaluated the recently developed genome-wide fragmentome approach (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>) as a molecular tool for detecting response to therapy in these same patients with metastatic pancreatic cancer. We have previously shown that genome-wide analyses of cfDNA can be used to evaluate underlying genomic, chromatin, and epigenomic changes specific to cancer (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>, <xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>, <xref rid="R44" ref-type="bibr"><italic toggle="yes">44</italic></xref>). To evaluate cfDNA fragmentation in the plasma from patients in the CheckPAC trial, we examined fragmentation profiles reflecting the size and distribution of tens of millions of fragments in 473 nonoverlapping 5-Mb regions and spanning approximately 2.4 Gb of the genome. Analysis of the fraction of short [100 to 150 base pairs (bp)] to long (151 to 220 bp) cfDNA fragments in each of 473 5-Mb bins revealed greater heterogeneity within patients at baseline or with disease progression as compared to those who experienced stable disease or a partial response (fig. S8).</p><p>As the cfDNA fragmentome may comprise changes related to large-scale genomic changes released from cancer cells (<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>), we also examined chromosomal gains and losses in the circulation of these patients. For samples obtained at the baseline time point with ctDNA levels above 10% as quantified by WGMAF, we found statistically significant correlations of arm chromosomal gains and losses in plasma and matched tumor (all correlations with correlation coefficient&#x000a0;&#x0003e; 0.64 and <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). The paired plasma-tumor copy number changes reflected those commonly found in pancreatic cancer including gains in 1q, 8q, 5p, and 7p as well as losses in 1p, 3p, 6p, 6q, 9p, 17p, and 18q (<xref rid="F3" ref-type="fig">Fig. 3B</xref>) (<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>, <xref rid="R46" ref-type="bibr"><italic toggle="yes">46</italic></xref>). We found that, at the on-treatment time point, patients with partial clinical response had fewer copy number alterations than those with stable disease, who in turn had fewer than those with progressive disease (<xref rid="F3" ref-type="fig">Fig. 3B</xref>). These analyses demonstrate not only that chromosomal changes found in the circulation reflect the known biology of pancreatic cancer but that they may also reflect changes in tumor burden in response to therapy (<xref rid="F3" ref-type="fig">Fig. 3B</xref>).</p><fig position="float" id="F3" fig-type="image" specific-use="distribute"><label>Fig. 3.</label><caption><title>cfDNA fragmentation features reflect underlying tumor biology in pancreatic cancer.</title><p>(<bold>A</bold>) Changes in the cell-free chromosomal arm content in the circulation (plasma <italic toggle="yes">z</italic> scores) compared to the changes in chromosome arm content in tumors (tumor median log ratio) for patients who had greater than 10% plasma MAF by WGMAF. (<bold>B</bold>) Fraction of cases with copy number variation (CNV) changes by chromosomal arm for PDAC cancers in TCGA are shown alongside assessment of copy number changes in CheckPAC patients, as quantified by the median log ratio by arm for tumor copy number gains and losses, as well as <italic toggle="yes">z</italic> scores by arm for all patients with plasma samples at baseline and at follow-up for each of the clinical RECIST 1.1 response categories.</p></caption><graphic xlink:href="sciadv.ads5002-f3" position="float"/></fig><p>To examine the contribution of pancreatic cancer to the cfDNA, we compared high-throughput sequencing chromosome conformation capture open (A) and closed (B) compartments of reference pancreatic cancers and lymphoblastoid samples (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>) to plasma samples from healthy individuals or those within the CheckPAC trial (<xref rid="F4" ref-type="fig">Fig. 4</xref>) (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>). Assessing the six patient samples with the highest ctDNA tumor burden revealed that these contained contributions that were similar to healthy individuals as well as a one that related to the cancer samples. While healthy control plasma samples were highly correlated to lymphoblastoid cell lines, pancreatic cancer plasma samples and the extracted pancreatic cancer component were more similar to the pancreatic cancer A/B compartments. These analyses demonstrate that cfDNA from patient samples in the CheckPAC trial reflects a combination of chromatin compartments from both peripheral blood cells and pancreatic cancer.</p><fig position="float" id="F4" fig-type="image" specific-use="distribute"><label>Fig. 4.</label><caption><title>Genome-wide cfDNA fragmentation profiles comprise chromatin structures from peripheral blood cells and pancreatic cancer.</title><p>Comparison of plasma fragmentation features to reference A/B compartments across chromosome 14. The first panel shows chromatin A/B compartments derived from pancreatic cancer tissue methylation (<xref rid="R36" ref-type="bibr"><italic toggle="yes">36</italic></xref>). The second panel shows a median deconvoluted pancreatic cancer component based on the six samples with the highest ctDNA levels. The third panel shows the median fragmentation profile in the plasma for those samples, and the fourth panel shows the median fragmentation profile for a set of healthy plasma controls. The final panel shows chromatin A/B compartments for lymphoblast cells. Dark shading indicates regions of the genome where the two reference tracks are discordant in domain (open/closed) or magnitude. The extracted pancreatic cancer component has the greatest similarity to the pancreatic cancer reference track, and the healthy plasma has the greatest similarity to the lymphoblast reference track.</p></caption><graphic xlink:href="sciadv.ads5002-f4" position="float"/></fig><p>We have previously shown that fragmentation patterns analyzed by DELFI are also influenced by structural and epigenetic changes in genome-wide repeat elements including long interspersed nuclear elements, short interspersed nuclear elements, long terminal repeats, and satellites and transposable elements and could be assessed using ARTEMIS, an alignment-free method allowing granular assessment of repeat elements in low-coverage WGS of cfDNA (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>). The multitude of fragmentation, chromosomal, epigenetic, and repeat landscape features showed widespread changes among the CheckPAC samples analyzed (<xref rid="F5" ref-type="fig">Fig. 5</xref>). A locked ensemble model of 2343 features from the ARTEMIS and DELFI fragmentomic approaches (<xref rid="R32" ref-type="bibr"><italic toggle="yes">32</italic></xref>) was used to generate a joint ARTEMIS-DELFI score for all CheckPAC samples (fig. S9 and table S5), reflecting the probability that an individual&#x02019;s plasma sample contains tumor derived DNA.</p><fig position="float" id="F5" fig-type="image" specific-use="distribute"><label>Fig. 5.</label><caption><title>Heatmap of clinical features and cfDNA fragmentation and genomic repeat features.</title><p>The vertical axis is categorized by all patients with plasma samples at baseline and at follow-up for each of the clinical RECIST 1.1 response categories and sorted by ARTEMIS-DELFI scores in descending order. All molecular features evaluated are plotted along the horizontal axis and colored by feature type. The heatmap color scale reflects the deviation of cfDNA features as compared to the mean of noncancer individuals.</p></caption><graphic xlink:href="sciadv.ads5002-f5" position="float"/></fig><p>While baseline samples of CheckPAC patients (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;36) had relatively high ARTEMIS-DELFI scores, with a median score of 0.93 (95% CI&#x000a0;=&#x000a0;0.65 to 0.93) (<xref rid="F6" ref-type="fig">Fig. 6A</xref>), landmark samples at the 8-week time point revealed very low on-treatment ARTEMIS-DELFI measurements (median score&#x000a0;=&#x000a0;0.15, 95% CI&#x000a0;=&#x000a0;0.075 to 0.38) for patients who were determined to be partial responders (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;6) using BORs by RECIST 1.1, whereas patients with stable disease (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;11) (median SD score&#x000a0;=&#x000a0;0.38, 95% CI&#x000a0;=&#x000a0;0.30 to 0.81) or progressive disease (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;15) (median PD scores&#x000a0;=&#x000a0;0.68, 95% CI&#x000a0;=&#x000a0;0.45 to 0.90) had higher ARTEMIS-DELFI scores (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.017 for all comparisons, Wilcoxon signed-rank test) (<xref rid="F6" ref-type="fig">Fig. 6A</xref> and figs. S1 and S10).</p><fig position="float" id="F6" fig-type="image" specific-use="distribute"><label>Fig. 6.</label><caption><title>ARTEMIS-DELFI scores predict survival for patients in CheckPAC trial.</title><p>(<bold>A</bold>) Boxplot of ARTEMIS-DELFI scores for all patients with plasma samples at baseline, and at follow-up for each of the clinical RECIST 1.1 response categories. (<bold>B</bold>) Kaplan-Meier curves of progression-free survival probability and OS probability based on median landmark ARTEMIS-DELFI score at 8 weeks. Patients are classified as responders or nonresponders if follow-up ARTEMIS-DELFI scores are below or above the median follow-up score, respectively. (<bold>C</bold>) Kaplan-Meier curves of progression-free survival probability and OS probability based on &#x0201c;fast-fail&#x0201d; landmark ARTEMIS-DELFI score after one cycle of treatment (2 weeks). Patients are classified as responders or nonresponders if follow-up ARTEMIS-DELFI scores are below or above the median follow-up score, respectively</p></caption><graphic xlink:href="sciadv.ads5002-f6" position="float"/></fig><p>Using the median on-treatment landmark ARTEMIS-DELFI score as a cut point for determining molecular response, we found that of the 32 patients analyzed (fig. S1A), 16 patients with scores below the cut point identified as molecular responders had a significantly longer PFS compared to 16 patients with scores above the cut point identified as molecular nonresponders (PFS of 105 days versus 53 days, respectively) (HR&#x000a0;=&#x000a0;0.28, 95% CI&#x000a0;=&#x000a0;0.12 to 0.67 <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0024, log-rank test). Similarly, molecular responders had a significantly longer OS compared to molecular nonresponders (OS of 233 days versus 172 days, respectively) (HR&#x000a0;=&#x000a0;0.12, 95% CI&#x000a0;=&#x000a0;0.046 to 0.31, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, log-rank test) (<xref rid="F6" ref-type="fig">Fig. 6B</xref>). For patients with stable disease by imaging at the 8-week time point (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;16), molecular response assessment by ARTEMIS-DELFI provided a similar stratification of OS, with molecular responders having a median OS of 399 days compared to 157 days for molecular nonresponders (HR&#x000a0;=&#x000a0;0.26, 95% CI&#x000a0;=&#x000a0;0.071 to 0.93, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0025, log-rank test) (fig. S11). These findings suggested that ARTEMIS-DELFI scores were significant predictors of outcome for patients with pancreatic cancer after initiation of immune checkpoint blockade.</p><p>To assess whether ARTEMIS-DELFI scores were independent predictors of OS when examined together with clinical risk factors of pancreatic cancer progression, we performed a multivariate analysis with factors known to be associated with outcomes for patients with pancreatic cancer (<xref rid="R42" ref-type="bibr"><italic toggle="yes">42</italic></xref>, <xref rid="R43" ref-type="bibr"><italic toggle="yes">43</italic></xref>) similar to the WGMAF analysis described earlier. In this multivariate analysis, we found that on-treatment, ARTEMIS-DELFI scores were significantly associated with patient OS (HR&#x000a0;=&#x000a0;55, 95% CI&#x000a0;=&#x000a0;8.2 to 361, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, Cox proportional hazards) (<xref rid="F7" ref-type="fig">Fig. 7A</xref>), while clinical characteristics did not affect outcome.</p><fig position="float" id="F7" fig-type="image" specific-use="distribute"><label>Fig. 7.</label><caption><title>Multivariate hazard analyses demonstrate on-treatment ARTEMIS-DELFI scores as independent predictors of OS for patients in the CheckPAC trial.</title><p>Multivariate Cox proportional hazard analyses were generated for each molecular method and fit to OS adjusting for clinical subgroups. Each of the indicated subgroups that have been shown to be significant on univariate analyses in previous studies (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>) have been included in the multivariate analysis. Hazard models are shown using (<bold>A</bold>) ARTEMIS-DELFI scores at baseline and 8-week follow-up values for patients in the CheckPAC study and (<bold>B</bold>) ARTEMIS-DELFI scores at baseline and after one cycle of treatment for patients in the CheckPAC study.</p></caption><graphic xlink:href="sciadv.ads5002-f7" position="float"/></fig><p>We evaluated whether an analysis of patients with high ARTEMIS-DELFI scores (above the 75th percentile) at a 2-week time point after initiation of therapy (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;9) would allow for a rapid determination of response (&#x0201c;fast fail&#x0201d;). We found that patients with scores above this threshold had a significantly shorter median PFS and OS than patients with lower scores (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;27) (PFS of 48 days versus 88 days, respectively; HR&#x000a0;=&#x000a0;0.29, 95% CI&#x000a0;=&#x000a0;0.17 to 0.66, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0017, log-rank test) (OS of 110 days versus 230 days, respectively; HR&#x000a0;= 0.35, 95% CI&#x000a0;=&#x000a0;0.16 to 0.78, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0074, log-rank test) (<xref rid="F6" ref-type="fig">Fig. 6B</xref>), and remained significant even in multivariate analysis (HR&#x000a0;=&#x000a0;14.60, 95% CI&#x000a0;=&#x000a0;1.25 to 170.20, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.03, Cox proportional hazards) (<xref rid="F7" ref-type="fig">Fig. 7B</xref>). These findings suggested that ARTEMIS-DELFI scores were potentially useful predictors of outcome for patients with pancreatic cancer even after one treatment cycle of immune checkpoint blockade.</p></sec><sec disp-level="2"><title>Comparison to other methodologies of molecular response assessment</title><p>We examined how the molecular approaches described above compared to each other as well as existing methodologies for evaluating tumor burden, including RECIST 1.1 classification, CA19-9 serum measurement, and ichorCNA (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). We first compared ARTEMIS-DELFI and WGMAF scores to each other from across all evaluable time points and found that they were highly correlated (<italic toggle="yes">R</italic>&#x000a0;=&#x000a0;0.84, Pearson correlation, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;2.2 &#x000d7; 10<sup>&#x02212;16</sup>, Wilcoxon signed-rank test) (fig. S12). While all patients in the CheckPAC trial had cancer, we considered plasma samples from patient CGPLPA223 as not harboring any ctDNA after this patient had a complete long-term response and use the genome-wide MAF scores in these samples to determine the limit of blank ARTEMIS-DELFI. The median WGMAF score for these ctDNA negative samples was 0.0081% (range less than 0.0069 to 0.028%) corresponding to an ARTEMIS-DELFI score of 0.045 (table S5). Using the range of ctDNA MAF values obtained by WGMAF in the remaining patient samples, we determined that 83% of samples tested positive with ARTEMIS-DELFI when WGMAF values were&#x000a0;&#x02265;0.001 (fig. S13).</p><p>In contrast to these approaches, RECIST 1.1 classification of the first follow-up CT scan did not stratify patients in the CheckPAC trial with respect to their OS, with patients classified as PR, PD, or SD having similar outcomes (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.15, log-rank test). In contrast, RECIST measurements for BOR ultimately stratified patients for OS (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.014, log-rank test) (fig. S14). For CA19-9, we found that after removing four patients with CA19-9&#x000a0;&#x0003c;37 U/ml at baseline (patients whose tumors do not secrete CA19-9) (<xref rid="R48" ref-type="bibr"><italic toggle="yes">48</italic></xref>), the remaining patients who were clinical responders had a statistically significant lower levels of this protein at an equivalent 8-week time point (fig. S15) (median CA19-9 of patients with partial response&#x000a0;=&#x000a0;177 U/ml, 95% CI: 12 to 1300 U/ml) compared to those with progressive disease at follow-up (median CA19-9 of patients with progressive disease = 5630 U/ml, 95% CI&#x000a0;=&#x000a0;1400 to 26,000 U/ml, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0046, Wilcoxon signed-rank test) (fig. S16A). However, patients with clinical response did not have a significant difference in mean CA19-9 levels compared to patients with stable disease or patients at baseline (median CA19-9 of patients with stable disease = 882 U/ml, 95% CI: 250 to 6800 U/ml, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.18, Wilcoxon signed-rank test) (fig. S16B). Similarly for patients with tumor levels quantified by ichorCNA, we found that at the 8-week time point, there was no significant difference between individuals with a partial response (median ichorCNA MAF&#x000a0;=&#x000a0;1.4%, 95% CI: 0.12 to 1.6%) and those with progressive disease (median ichorCNA MAF&#x000a0;=&#x000a0;2.2%, 95% CI: 1.9 to 12%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.34, Wilcoxon signed-rank test). However, patients with partial response had significantly lower tumor fractions than those with stable disease [ichorCNA tumor fraction&#x000a0;=&#x000a0;4.9% (95% CI&#x000a0;=&#x000a0;2.5 to 5.3%)] (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.041, Wilcoxon signed-rank test) (fig. S17).</p><p>We also compared ARTEMIS-DELFI or WGMAF scores with CA19-9 measurements for individuals who were CA19-9 secretors and found that although there was significant correlation with each of these with CA19-9 [for ARTEMIS-DELFI <italic toggle="yes">R</italic> = 0.49 (Pearson correlation), <italic toggle="yes">P</italic> &#x0003c;&#x000a0;0.0001, Wilcoxon signed-rank test and for WGMAF <italic toggle="yes">R</italic>&#x000a0;=&#x000a0;0.55 (Pearson correlation), <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, Wilcoxon signed-rank test], it was weaker than when WGMAF and ARTEMIS-DELFI were compared to each other, and that for patients who were nonsecretors, there was no correlation (for ARTEMIS-DELFI <italic toggle="yes">R</italic>&#x000a0;=&#x000a0;&#x02212;0.021, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.95, Wilcoxon signed-rank test and for WGMAF <italic toggle="yes">R</italic>&#x000a0;=&#x000a0;0.27, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.66, Wilcoxon signed-rank test) (fig. S18). Overall, these analyses suggest that existing approaches may be inadequate for accurate determination of response to therapy in patients with pancreatic cancer.</p><p>We compared longitudinal profiles for all patients enrolled in the CheckPAC trial, showing the dynamics of WGMAF and ARTEMIS-DELFI scores over time as compared to RECIST scoring, lesion size, targeted MAF, and CA19-9 measurements (fig. S19). WGMAF could not be performed in 14 patients either due to lack of suitable tumor biopsy or insufficient mutations observed after whole-genome analyses, while ARTEMIS-DELFI analyses were performed in all 40 patients. Analyzable patients could largely be categorized as either molecular responders or nonresponders. As examples, patient CGPLPA223 had a molecular response at 8 weeks, while patient CGPLPA220 was a molecular nonresponder at the same time point (<xref rid="F8" ref-type="fig">Fig. 8</xref>). For both patients, the first follow-up CT scan at this 8-week time point indicated stable disease. For patient CGPLPA223, the partial response was ultimately observed at the third follow-up CT scan (week 24), while for patient CGPLPA220, progressive disease was indicated at the next scan (week 15).</p><fig position="float" id="F8" fig-type="image" specific-use="distribute"><label>Fig. 8.</label><caption><title>Example of a molecular responder and nonresponder to treatment using different methodologies.</title><p>Response to treatment is shown for a patient with clinical BOR of partial response (<bold>A</bold>) and stable disease (<bold>B</bold>). Patient clinical paths are shown in the top panels, followed by methodologies for monitoring response to treatment. For the top panels, patient treatment is indicated in the top two rows, radiologic assessments are plotted in the third row, and the last follow-up is indicated in the fourth row. Sum of target lesions were assessed from standard-of-care CT scans. WGMAF, targeted MAF, and ARTEMIS-DELFI scores are plotted for each of the blood draw time points. CA19-9 was measured clinically at regular intervals throughout treatment.</p></caption><graphic xlink:href="sciadv.ads5002-f8" position="float"/></fig><p>Although landmark studies at the 8-week time point have logistical advantages of only requiring a single sample for analysis, we also used the WGMAF and a variation of the DELFI approach to compare changes in ctDNA over time. Evaluation of any increases or decreases in WGMAF levels from baseline to the 8-week time point resulted in a significant difference in progression-free survival (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.018, log-rank test) but not OS (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.16, log-rank test) for patients who were evaluated using this approach (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;17) (fig. S20). Although ARTEMIS-DELFI scores are not linearly related to MAF levels and therefore cannot be used directly for quantitative measurement of MAF levels over time, we used a variation of DELFI (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>), called DELFI-TF, which was specifically designed to measure changes in ctDNA levels, and found that grouping patients by increasing (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;8) or decreasing (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;20) DELFI-TF scores between baseline and the 8-week time point was predictive of OS (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0047, log-rank test) and PFS (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.00012, log-rank test) in the patients (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;28) where samples were available (fig. S21).</p></sec><sec disp-level="2"><title>Validation in external cohort</title><p>We assessed whether our liquid biopsy approach would provide a molecular stratification predictive of clinical end points in the PACTO trial. As this trial did not collect tumor tissue, we could only examine the ARTEMIS-DELFI approach and evaluated the same locked ARTEMIS-DELFI model at the same 8-week time point evaluated in the CheckPAC cohort, however using median on-treatment score from PACTO as cut point (figs. S9, S21, and S22, and table S6). Molecular responders had a significantly longer OS than nonresponders (OS: 288 days compared to 199 days, HR&#x000a0;=&#x000a0;0.488, 95% CI&#x000a0;=&#x000a0;0.24 to 1.01, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.048, log-rank test) (fig. S23A and table S6). We found a trend in PFS differences between patients with molecular response (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;16) compared to those without molecular response (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;16) (PFS: 207 days compared to 139 days, respectively) (HR&#x000a0;=&#x000a0;0.54, 95% CI&#x000a0;=&#x000a0;0.26 to 1.14, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.096, log-rank test) (fig. S23 and table S6). A multivariate hazard analysis of this cohort revealed that the on-treatment ARTEMIS-DELFI score was a statistically significant predictor of OS (HR&#x000a0;=&#x000a0;5.46, 95% CI&#x000a0;=&#x000a0;1.44 to 20.66, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.01, log-rank test). (<xref rid="F9" ref-type="fig">Fig. 9A</xref>). Imaging at this time point revealed that RECIST 1.1 assessment was not associated with OS (fig. S24). These results suggest that the association between changes in ARTEMIS-DELFI scores and patient survival during therapy are generalizable across treatment settings for patients with late-stage pancreatic cancer.</p><fig position="float" id="F9" fig-type="image" specific-use="distribute"><label>Fig. 9.</label><caption><title>Multivariate hazard analyses demonstrate on-treatment ARTEMIS-DELFI scores as independent predictors of OS for patients in the PACTO trial.</title><p>Multivariate Cox proportional hazard analyses were generated for each molecular method and fit to OS adjusting for clinical subgroups. Each of the indicated subgroups that have been shown to be significant on univariate analyses were included in the multivariate analysis. Hazard models are shown using (<bold>A</bold>) ARTEMIS-DELFI scores at baseline and 8-week follow-up for patients in the PACTO study and (<bold>B</bold>) ARTEMIS-DELFI scores at baseline and after one cycle of treatment for patients in the PACTO study.</p></caption><graphic xlink:href="sciadv.ads5002-f9" position="float"/></fig><p>We evaluated whether the fast fail analysis of patients with high ARTEMIS-DELFI scores (above the 75th percentile) after one cycle of treatment (4-week time point) in this cohort (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;9) would allow for a rapid determination of response. We found that patients with scores above this threshold had a significantly shorter median PFS and OS than patients with lower scores (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;27) (PFS of 106 days versus 196 days respectively, HR&#x000a0;=&#x000a0;0.27, 95% CI&#x000a0;=&#x000a0;0.11 to 0.67, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.0027, log-rank test), (OS of 151 days versus 280 days respectively, HR&#x000a0;=&#x000a0;0.17, 95% CI&#x000a0;=&#x000a0;0.064 to 0.46, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.00011, log-rank test) (fig. S23B), and remained significant even in a multivariate analysis (HR&#x000a0;=&#x000a0;7.19, 95% CI&#x000a0;=&#x000a0;1.84 to 28.07, <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.01, Cox proportional hazards) (<xref rid="F9" ref-type="fig">Fig. 9B</xref>). These findings validated that ARTEMIS-DELFI scores were potentially useful early predictors of outcome for patients with pancreatic cancer.</p></sec></sec><sec sec-type="discussion" disp-level="1"><title>DISCUSSION</title><p>In this study, we developed and evaluated two approaches for noninvasive cfDNA monitoring for patients with pancreatic cancer: a tumor-informed mutation-based approach (WGMAF) and a tumor-independent fragmentation-based approach (ARTEMIS-DELFI). We found that both WGMAF and ARTEMIS-DELFI scores after initiation of therapy were significantly associated with PFS and OS in the CheckPAC trial. In addition, the ARTEMIS-DELFI approach was successfully validated in the plasma-only PACTO trial. These approaches were better predictors of outcome than imaging or other existing clinical and molecular markers at 2 months after treatment initiation.</p><p>The tumor- and mutation-informed WGMAF methodology provides a unique approach to mutation-based analyses of tumor-derived cfDNA in the circulation. By taking advantage of knowledge of the specific mutations in a patient&#x02019;s tumor, the approach can be personalized for monitoring an individual patient&#x02019;s cancer. Use of a genome-wide approach permits the laboratory processes to be standardized across patients and does not require development of new PCR or mutation-related probes for each patient as is necessary for other methods (<xref rid="R49" ref-type="bibr"><italic toggle="yes">49</italic></xref>). This approach is not cancer-type specific and has the potential to be applied in a variety of treatment settings. A clear weakness of the approach, however, is that it requires a tumor biopsy and sufficient tumor-derived DNA and, therefore, may not be applicable for all patients. In the CheckPAC trial of patients with advanced pancreatic cancer, half of the patients could not be analyzed because of these limitations.</p><p>In contrast to WGMAF, the ARTEMIS-DELFI approach is tumor-and mutation-independent and can be applied even in settings where no tumor tissue is available for analysis. This approach does not rely on knowledge of specific mutations in a patient&#x02019;s tumor, nor does it use a targeted panel. The ARTEMIS-DELFI method leverages the fragmentation features in addition to the repeat landscape across noncoding regions of the genome, hence deriving signal from a truly genome-wide picture of genomic, epigenomic and chromatin changes in cancer. Given the ease of obtaining plasma samples from patients, and the limited cfDNA used, all patients under evaluation were successfully analyzed.</p><p>While the CheckPAC and PACTO studies have provided substantial evidence that cfDNA analyses using WGMAF and ARTEMIS-DELFI correlate with patient outcome, the number of patients enrolled in both trials was limited. In addition, some serial blood sample time points did not correspond directly to dates of CT scans, and, therefore, they could not be directly compared. As is true for most studies of patients with pancreatic cancer, there were few responders in these trials, and, therefore, the number of patients with molecular responses represents a small subset of patients in these trials. In addition, cut points for determining molecular response in this study were not prespecified and based on quantiles of the observed responses in both the training and validation sets. Future studies in larger cohorts of patients with other types of cancer are needed to validate these methodologies.</p><p>In future clinical settings, these cfDNA-based methods could be used for monitoring patients over the course of treatment and making real-time clinical decisions about therapy regimens. Although both molecular approaches may be useful, the choice of which method to use may depend on the specific clinical application and sample availability. For patients with pancreatic cancer, methods for monitoring patients during therapy may be particularly important given the multitude of new avenues that are emerging for targeted and immune therapies.</p></sec><sec sec-type="methods" disp-level="1"><title>METHODS</title><sec disp-level="2"><title>Sample collection</title><p>We examined 217 plasma samples for 40 of the 84 patients enrolled in a prospective study, CheckPAC (NCT02866383), at Copenhagen University Hospital&#x02013;Herlev and Gentofte (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>). In addition, we examined 205 plasma samples available for 40 of the 137 patients enrolled in a prospective study, PACTO (NCT02767557) (<xref rid="R33" ref-type="bibr"><italic toggle="yes">33</italic></xref>), at Copenhagen University Hospital&#x02013;Herlev and Gentofte. Material was examined as per the clinical study protocol. All patients provided informed consent, in agreement with the Helsinki Declaration. Patients also provided signed informed consent to be included in the Danish BIOPAC study &#x0201c;BIOmarkers in patients with PAncreatic Cancer (BIOPAC) - can they provide new information of the disease and improve diagnosis and prognosis of the patients?&#x0201d; (NCT03311776; <ext-link xlink:href="http://www.herlevhospital.dk/BIOPAC" ext-link-type="uri">www.herlevhospital.dk/BIOPAC</ext-link>). The BIOPAC study protocol has been approved by the Danish Ethics Committee (VEK, j.nr. KA-20060113) and the Danish Data Protection Agency (j.nr. 2006-41-6848, 2012-58-0004; HGH-2015-027; I-Suite j.nr. 03960; and PACTICUS P-2020-834). The study was conducted in accordance with the Declaration of Helsinki. At scheduled intervals throughout the course of treatment, patients had blood collected for research purposes. Patient tumor biopsies were performed before treatment initiation and 2 weeks after radiation treatment. At each sampling, two cancerous lesions were biopsied, and two cores were taken from each of the lesions. One core was formalin fixed and paraffin embedded and used for generation of slides with hematoxylin and eosin staining, while the other core was designated for molecular analyses. Half of the molecular analysis core was fresh frozen for genomic analyses. Frozen cores were kept at -80&#x000b0;C for long-term storage. Blood samples were collected in EDTA tubes and, within 3 hours after blood sampling, centrifuged at 2300<italic toggle="yes">g</italic> for 10&#x000a0;min at 4&#x000b0;C to separate plasma from buffy coat and red blood cell fractions. The EDTA plasma was stored in cryovials at &#x02212;80&#x000b0;C until analysis. One milliliter of buffy coat was removed from each sample and stored in a cryovial at &#x02212;80&#x000b0;C. Before analysis, the plasma fraction was thawed and spun at high speed of 18,000 <italic toggle="yes">g</italic> for 10&#x000a0;min to precipitate any remaining solid fraction. Liquid plasma fraction was aliquoted into cryovials and kept at &#x02212;80&#x000b0;C for long-term storage.</p></sec><sec disp-level="2"><title>Tumor and buffy coat sample processing</title><p>Forty of the 43 patients in the CheckPAC study had plasma samples available. Frozen biopsies of the patients&#x02019; cancers that were available and had sufficient pathologic cellularity were selected for sequencing. Preference was given to pretreatment biopsies from a site that would not receive radiation, although in cases of insufficient material or cellularity, on-treatment and irradiated samples were sequenced. We evaluated tumor and matched buffy coat for the subset of 34 patients. Sample preparation and bioinformatic analyses of tumor and buffy coat samples were performed as previously described (<xref rid="R50" ref-type="bibr"><italic toggle="yes">50</italic></xref>). Briefly, DNA was extracted from matched frozen tumor tissue and buffy coat samples using the Qiagen DNA FFPE Tissue Kit or Qiagen DNA Blood Mini Kit (Qiagen GmbH). Genomic libraries were prepared and whole-genome sequenced on Illumina NovaSeq 6000 S4 flow cells with 100-bp reads (table S3).</p></sec><sec disp-level="2"><title>Plasma sample processing</title><p>Circulating cfDNA was isolated from frozen plasma using Qiagen QIAamp Circulating Nucleic Acids Kit (Qiagen GmbH) from a median of 2.6&#x000a0;ml (range: 1 to 4&#x000a0;ml) of plasma, which was eluted in 52 &#x003bc;l of ribonuclease-free water with 0.04% sodium azide (Qiagen GmbH.). DNA was quantified, and quality was assessed from 1 &#x003bc;l of DNA eluate using Agilent 2100 Bioanalyzer automated electrophoresis platform, using DNA 1000 assay and chip. This yielded a median of 58.2 ng of DNA from each sample (range: 1.4 to 2600 ng). DNA was stored in LoBind tubes (Eppendorf AG) at &#x02212;20&#x000b0;C. Concentration and quality of cfDNA were assessed using the Bioanalyzer 2100 (Agilent Technologies).</p><p>Samples were organized for next-generation sequencing (NGS) library preparation in batches of 11 to 26 samples. All sample time points for each patient were batched together, and each batch contained one nucleosome-digested control of healthy DNA (tables S5 and S6).</p><p>NGS cfDNA libraries were prepared for WGS using a maximum of 15 ng of cfDNA (tables S5 and S6). In brief, genomic libraries were prepared using the NEBNext DNA Library Prep Kit for Illumina (New England Biolab) with four main modifications to the manufacturer&#x02019;s guidelines: (i) The library purification steps followed the on-bead AMPure XP (Beckman Coulter) approach to minimize sample loss during elution and tube transfer steps; (ii) NEBNext End Repair, A-tailing, and adapter ligation enzyme and buffer volumes were adjusted as appropriate to accommodate on-bead AMPure XP purification; (iii) Illumina dual index adapters were used in the ligation reaction; and (iv) cfDNA libraries were amplified with Phusion Hot Start Polymerase. All samples underwent a four-cycle PCR amplification after the DNA ligation step. Samples were run on Illumina NovaSeq 6000 S4 flow cells with 2 &#x000d7; 100&#x02013;bp read length at a coverage of 2 to 3&#x000d7;. Sequencing data were output into FASTQ file format.</p><p>For 10 patients in the CheckPAC trial, targeted sequencing was performed using the targeted error correction sequencing (TEC-Seq) approach to evaluate 64 well-known cancer driver genes (<xref rid="R51" ref-type="bibr"><italic toggle="yes">51</italic></xref>). This method used the PlasmaSELECT 64 gene panel from Personal Genome Diagnostics and is based on targeted capture and deep sequencing (&#x0003e;30,000&#x000d7;) of DNA fragments and enables identification of tumor-specific alterations in ctDNA while distinguishing these from amplification and sequencing artifacts, germline changes, or alterations related to blood cell proliferation that may be present in cfDNA.</p></sec><sec disp-level="2"><title>Preprocessing of sequencing data</title><p>Before alignment, adapter sequences were filtered from reads using fastp version 0.20.0 (<xref rid="R52" ref-type="bibr"><italic toggle="yes">52</italic></xref>). Sequence reads were aligned against the hg19 human reference genome using Bowtie2 version 2.3.0 (<xref rid="R53" ref-type="bibr"><italic toggle="yes">53</italic></xref>), and duplicate reads were removed using Sambamba 0.6.8 (<xref rid="R54" ref-type="bibr"><italic toggle="yes">54</italic></xref>) (plasma) or Samtools version 1.18 (<xref rid="R55" ref-type="bibr"><italic toggle="yes">55</italic></xref>) (tumor and buffy coat).</p></sec><sec disp-level="2"><title>Selection of sample time points</title><p>Patient baseline time points were selected as the plasma draw that occurred before treatment initiation. Follow-up evaluation time point was selected as the second blood draw that occurred after treatment initiation, with a median of 55 days (fig. S2B and tables S5 and S6).</p></sec><sec disp-level="2"><title>Estimation of cfDNA MAF from WGS</title><p>Somatic single-base substitutions were identified in tumor tissue from a joint analysis of tumor and matched normal WGS data using Strelka2 version 2.9.0 (<xref rid="R56" ref-type="bibr"><italic toggle="yes">56</italic></xref>). Variant Call Format (VCF) files were filtered for candidate variants passing all Strelka2 filters (VCF FILTER field set to PASS). We further filtered variant calls to require (i)&#x000a0;&#x02265;3 mutant tier 1 reads from the tumor, (ii)&#x000a0;&#x02265;10% MAF of tier 1 reads from the tumor (iii)&#x000a0;&#x02265;30&#x000d7; coverage of tier 1 reads from the matched normal, (iv) zero mutant tier 1 reads from the matched normal, and (v)&#x000a0;&#x02264;5% MAF of tier 2 reads from the matched normal. In addition, we removed any candidate variants that were in the gnomAD database (version 3.0) with an allele frequency&#x000a0;&#x0003e;1 in 10,000, or if the variant did not pass gnomAD quality filters.</p><p>For each genomic position harboring a somatic mutation in the tumor after filtering (variant positions), we determined the base call of overlapping reads in cfDNA sequencing data using the pileup method in pysam version 0.16.0.1. Only proper read pairs with the highest mapping quality (MAPQ) of 42 were considered and reads flagged as PCR or optical duplicates as well as read pairs where either mate contained &#x02265;5 uncalled (<italic toggle="yes">N</italic>) bases were excluded. Furthermore, we required that bases from both read 1 and read 2 of a read pair overlapped a given variant position with Phred score&#x000a0;&#x02265;30, contained either the reference or the mutant allele, and agreed on the base call. A single MAF value was computed for each cfDNA sample as the number of observed mutant bases divided by the total number of bases analyzed after filtering, where counts were summed across all variant positions, genome wide.</p><p>Validation of WGMAF was performed using targeted sequencing TEC-Seq approach from PGDx (<xref rid="R51" ref-type="bibr"><italic toggle="yes">51</italic></xref>) of a subset of patients in CheckPAC trial. For all patients with <italic toggle="yes">KRAS</italic> mutations, we used the <italic toggle="yes">KRAS</italic> MAF values for comparison. In the case of patient CGPLPA223, where no <italic toggle="yes">KRAS</italic> mutation was detected, we selected the highest observed MAF in <italic toggle="yes">CTNNB1</italic>.</p></sec><sec disp-level="2"><title>Fragmentation analysis</title><p>Fragmentation features were calculated as previously described (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>). Briefly, each aligned pair was converted to a genomic interval representing the sequenced DNA fragment using bedtools 2.29.0 (<xref rid="R57" ref-type="bibr"><italic toggle="yes">57</italic></xref>). Only reads with a MAPQ score of at least 30 were retained. Read pairs were further filtered if overlapping the Duke Excluded Regions blacklist (<ext-link xlink:href="https://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&#x00026;g=wgEncodeMapability" ext-link-type="uri">https://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&#x00026;g=wgEncodeMapability</ext-link>). To capture large-scale epigenetic differences in fragmentation across the genome estimable from low-coverage WGS, we tiled the hg19 reference genome into nonoverlapping 5-Mb bins. Bins with an average GC base content&#x0003c;0.3 and an average mappability &#x0003c;0.9 were excluded, leaving 473 bins spanning approximately 2.4 Gb of the genome. GC correction was performed independently for short (&#x0003c;150 bp) and long (&#x02265;150 bp) cfDNA fragments using an external panel of 20 individuals without cancer sequenced on a NovaSeq to generate a target distribution. <italic toggle="yes">Z</italic> scores representing arm gains/losses were calculated for autosomal chromosome arms from the total number of aligned fragments and then centered and scaled by the mean representation and standard deviation from an external reference set as previously described (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>).</p></sec><sec disp-level="2"><title>Chromatin structure analysis</title><p>PDAC A/B compartments were generated from TCGA methylation data according to (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>). We used reference lymphoblastoid cell line Hi-C data from <ext-link xlink:href="https://github.com/Jfortin1/HiC_AB_Compartments" ext-link-type="uri">https://github.com/Jfortin1/HiC_AB_Compartments</ext-link>, as described previously (<xref rid="R47" ref-type="bibr"><italic toggle="yes">47</italic></xref>). The two reference tracks were compared to identify informative 100-kb bins, defined as bins where the chromatin domain differed between the two reference tracks or the magnitude difference in eigenvalues corresponded to a <italic toggle="yes">z</italic> score greater than 1.96 or less than &#x02212;1.96 (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.05) across all eigenvalue differences. The median fragmentation profile for six CheckPAC samples with high estimated tumor fraction by WGMAF and 10 randomly selected individuals without cancer was calculated. This information was used to extract an estimated median PDAC component in the plasma weighted by the WGMAF value of the individual plasma samples.</p></sec><sec disp-level="2"><title>ARTEMIS-DELFI score calculation</title><p>We computed kmer repeat landscapes for all samples as previously described (<xref rid="R30" ref-type="bibr"><italic toggle="yes">30</italic></xref>). We selected 786 features with more than 1000 kmers per million aligned reads and centered and scaled kmer counts within each sample across repeat families. We also computed GC corrected coverage in 559 1-Mb bins with high density of epigenetic marks. Using data from a prior multi-cancer cohort (LUCAS) (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>), we trained an ARTEMIS ensemble model to differentiate patients with cancer from those without. The ARTEMIS ensemble was composed of six penalized logistic regression (PLR) models with repeat landscapes as features (one PLR for each of five repeat families and for the epigenetic profile) that together generated the ARTEMIS score. We further trained two DELFI fragmentation feature models&#x02014;a PLR on the principal components capturing 95% of variance of the 473 bin-level fragmentation ratios, and a PLR on the chromosomal arm <italic toggle="yes">z</italic> scores. We ensembled the two scores from these models with the ARTEMIS score to train the ARTEMIS-DELFI model. The locked models trained on the LUCAS cohort (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>) were used to generate ARTEMIS-DELFI scores for the CheckPAC and PACTO cohorts. DELFI-TF analyses were performed as described in van&#x02019;t Erve <italic toggle="yes">et&#x000a0;al.</italic> (<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>).</p></sec><sec disp-level="2"><title>Tissue copy number analyses</title><p>Copy number analyses were performed on the tumor and matched buffy coat BAM files using FACETS version 0.5.0: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing (<xref rid="R45" ref-type="bibr"><italic toggle="yes">45</italic></xref>). Arm level copy number odds ratios were calculated as the median across FACETS-generated segments for each chromosomal arm. FACETS was also used to estimate tumor cellularity.</p><p>Copy number analyses were performed on the plasma BAM files using ichorCNA from the Broad Institute (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>). Arm level copy number odds ratios were calculated as the median across ichorCNA generated segments for each chromosomal arm. IchorCNA was also used to estimate plasma tumor fraction.</p></sec><sec disp-level="2"><title>Cox proportional hazards</title><p>We conducted Cox proportional hazards analyses to assess whether the values from WGMAF and ARTEMIS-DELFI independently predict OS. The multivariate models for WGMAF and ARTEMIS-DELFI were adjusted for treatment and clinical covariates previously reported in Johansen <italic toggle="yes">et&#x000a0;al.</italic> (<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>): ECOG PS, MGPS, age (greater than 65 years), sex, weight loss (greater than or equal to 5%), and bilirubin (greater than 25 &#x003bc;M).</p><p>In (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>), data from 84 patients were used to build a multivariate model to predict OS. WGS data were available for 40 patients in CheckPAC and 40 in PACTO. For analyses incorporating both baseline and on-treatment WGS data (ARTEMIS-DELFI or DELFI TF), we included a total of 29 patients. Because of the additional requirement of tumor samples for WGMAF, this analysis had a total of 17 patients. In PACTO, baseline and on-treatment WGS data were available for 32 samples.</p><p>In (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>), the authors performed univariate analyses to identify covariates for multivariate survival analysis by selecting covariates that were statistically significant with a type I error of 5%. We replicated the multivariate analysis from (<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>)&#x02014;a follow-up analysis to (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>)&#x02014;using a smaller sample size and omitting WGS data to observe changes in effect sizes and significance. Our analysis defined progression-free survival and OS from the start of treatment rather than the date of randomization; we verified that this change did not affect effect sizes or significance. After restricting the sample size to patients with WGS data, none of the covariates of (<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>) remained statistically significant. In (<xref rid="R58" ref-type="bibr"><italic toggle="yes">58</italic></xref>), MGPS, ECOG PS, bilirubin, and weight loss &#x02265;5% were significant covariates. In CheckPAC, none of the patients with WGS data had high bilirubin, so this variable was excluded. However, bilirubin was retained in PACTO because of the presence of patients with elevated levels. Data for ECOG PS and weight loss &#x02265;5% were unavailable for PACTO patients, so these variables were excluded in that study. The patients selected for multivariate analysis in CheckPAC were further narrowed to those with both baseline and on-treatment WGS data, and the findings remained unchanged: None of the clinical covariates were statistically significant.</p><p>We then conducted univariate analyses on the baseline and on-treatment values of DELFI TF, WGMAF, and ARTEMIS-DELFI in CheckPAC patients. Only on-treatment scores were significant, with HR&#x000a0;&#x0003e;1. Baseline scores were not significant for any, with HR&#x000a0;&#x0003c;1, except for ARTEMIS-DELFI, where HR&#x000a0;&#x0003e;1. Subsequently, we fit multivariate models incorporating both baseline and on-treatment values of DELFI TF, WGMAF, and ARTEMIS-DELFI. For DELFI TF and WGMAF, two model versions were tested: baseline with on-treatment values and baseline with the change in values (defined as the difference between on-treatment and baseline values). Note that effect sizes and significance for other covariates do not change in these versions, only the interpretation of the effects of baseline and on-treatment or baseline and change in values changes. In the model version with baseline and change in values, baseline values had HR&#x000a0;&#x0003e; 1. This is because keeping a fixed &#x0201c;change in values&#x0201d; implies raising on-treatment value when baseline value is raised. Since ARTEMIS-DELFI represents a cancer risk score ranging from 0 to 1, interpreting the difference between on-treatment and baseline values was deemed inappropriate, so this model version was excluded. To maintain consistent covariates across models, we opted to include baseline and on-treatment values in multivariate analyses. We applied a percentage change criterion to DELFI TF and WGMAF in CheckPAC, but these models did not validate in PACTO. We suspect that although DELFI TF and WGMAF values predict OS, study-related differences (e.g., previous therapies and treatment types) preclude the generalization of change-point cutoffs from one study to another. Therefore, we used continuous values for ARTEMIS-DELFI and standardized WGMAF in multivariate analysis. Treatment arm was added as a covariate to the models. CheckPAC and PACTO each had two arms: In CheckPAC, arm 1 received radiotherapy with nivolumab, and arm 2 received radiotherapy with nivolumab and ipilimumab; in PACTO, arm 1 received chemotherapy with nab-paclitaxel, and arm 2 received chemotherapy with nab-paclitaxel and tocilizumab.</p></sec><sec disp-level="2"><title>Statistical analysis</title><p>All statistical analyses were performed using R 4.4.0. Statistical significance of Kaplan-Meier survival curves was assessed using the log-rank test. HRs for OS and PFS clinical end points were calculated from univariate and multivariate Cox proportional hazards regression. CIs for WGMAF, ARTEMIS-DELFI, and ichorCNA were calculated on the logit scale and then transformed back to the nominal scale with the inverse logit. CIs and <italic toggle="yes">t</italic> tests for CA19-9 were evaluated on the log<sub>10</sub> scale.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>We thank members of our laboratories for critical review of the manuscript. We thank the research team at Copenhagen University Hospital&#x02013;Herlev and Gentofte for providing the extensive biobanking effort for the CheckPAC and PACTO trials. The results shown here are in part based on data generated by the TCGA Research Network (<ext-link xlink:href="https://cancer.gov/tcga" ext-link-type="uri">https://cancer.gov/tcga</ext-link>).</p><sec><p><bold>Funding:</bold> This work was supported in part by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to V.E.V., J.P., and R.B.S.); SU2C in-Time Lung Cancer Interception Dream Team Grant (to V.E.V. and J. P.); Stand Up to Cancer-Dutch Cancer Society International Translational Cancer Research Dream Team Grant (SU2C-AACR-DT1415) (to V.E.V.); the Gray Foundation (to V.E.V. and J.P.), the Honorable Tina Brozman Foundation (to V.E.V. and J.P.); the Commonwealth Foundation (to V.E.V. and R.B.S.); the Cole Foundation (to V.E.V.); a research grant from Delfi Diagnostics (to V.E.V. and R.B.S.); and the US National Institutes of Health grants CA121113 (to V.E.V.), 1T32GM136577 (to A.V.A), CA006973 (to V.E.V.), CA233259 (to V.E.V.), CA062924 (to V.E.V. and R.B.S.), and CA271896 (to V.E.V.). The CheckPAC trial was supported by Bristol Myers Squibb (BMS), which provided ipilimumab and nivolumab and financial support for data management (CA209-752). The PACTO trial was supported by Celgene/Bristol Myers Squibb (BMS), which provided drugs and financial support for data management (AX-CL-PANC-PI-007100). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research; the funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></sec><sec><p><bold>Author contributions:</bold> C.H., D.C.B., S.K., A.V.A., S.S., B.A., A.L., V.A., J.S.J., J.P., Z.H.F., R.B.S., and V.E.V. conceptualized the study, led the formal analysis and data visualization, and wrote the paper. I.M.C., N.A.V., S.S., K.B., and S.C. contributed to investigation and/or data visualization. I.M.C., S.T., and J.S.J. provided patient samples and clinical analyses. All authors reviewed, edited, and approved the manuscript before submission.</p></sec><sec><p><bold>Competing interests:</bold> A.V.A., R.B.S., and V.E.V. are inventors on patent applications submitted by Johns Hopkins University related to genome-wide repeat landscapes in cancer and cfDNA (US patent application number 63/532,642). A.V.A., D.C.B., V.A., Z.H.F., J.P., and R.B.S. are inventors on patent applications submitted by Johns Hopkins University related to cell-free DNA for cancer detection that have been licensed to Delfi Diagnostics. J.P., V.A., and R.B.S. are founders of Delfi Diagnostics, and V.A. and R.B.S are consultants for this organization. Z.L.S. and B.A. are employees of Delfi Diagnostics. V.E.V. is a founder of Delfi Diagnostics, serves on its Board of Directors, and owns Delfi Diagnostics stock, which is subject to certain restrictions under university policy. In addition, Johns Hopkins University owns equity in Delfi Diagnostics. V.E.V. divested his equity in Personal Genome Diagnostics (PGDx) to LabCorp in February 2022. V.E.V. is an inventor on patent applications submitted by Johns Hopkins University related to cancer genomic analyses and cell-free DNA that have been licensed to one or more entities, including Delfi Diagnostics, LabCorp, Qiagen, Sysmex, Agios, Genzyme, Esoterix, Ventana, and ManaT Bio. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. V.E.V. is an advisor to Viron Therapeutics and Epitope. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. I.M.C. has an advisory role at Amgen, AstraZeneca, Astella, and ANOCCA. I.M.C. has travel, accommodations, and expenses provided by Roche, Bristol Myers Squibb, Celgene, and Bayer. I.M.C has research funding from Roche (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Genis (Inst), and Varian Medical Systems (Inst), AstraZeneca (Inst), and GENMAB (Inst). J.S.J has research funding from Roche (Inst), Bristol Myers Squibb (Inst), and Celgene (Inst). Travel, as well as accommodations expenses from Roche, Bristol Myers Squibb, Celgene, and Bayer. The authors declare that they have no other competing interests.</p></sec><sec><p><bold>Data and materials availability:</bold> All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials or deposited in publicly available repositories. The code to run the ARTEMIS-DELFI pipeline is publicly available <ext-link xlink:href="https://github.com/cancer-genomics/artemis2024" ext-link-type="uri">https://github.com/cancer-genomics/artemis2024</ext-link>. Code needed to generate DELFI features for fragmentation-based analysis may be found at <ext-link xlink:href="https://github.com/cancer-genomics/reproduce_lucas_wflow" ext-link-type="uri">https://github.com/cancer-genomics/reproduce_lucas_wflow</ext-link>. The code to reproduce manuscript figures and analyses is publicly available <ext-link xlink:href="https://github.com/cancer-genomics/hruban_wflow" ext-link-type="uri">https://github.com/cancer-genomics/hruban_wflow</ext-link>. These github repositories have also been archived on Zenodo at <ext-link xlink:href="https://zenodo.org/records/15103837" ext-link-type="uri">https://zenodo.org/records/15103837</ext-link>. Sequence data generated for cfDNA samples have been deposited at the database of the European Genome-Phenome Archive (EGA) under accession codes EGAS50000000923 (<ext-link xlink:href="https://ega-archive.org/studies/EGAS50000000923" ext-link-type="uri">https://ega-archive.org/studies/EGAS50000000923</ext-link>) and EGAD50000001353 (<ext-link xlink:href="https://ega-archive.org/datasets/EGAD50000001353" ext-link-type="uri">https://ega-archive.org/datasets/EGAD50000001353</ext-link>) and may be obtained at <ext-link xlink:href="https://ega-archive.org/" ext-link-type="uri">https://ega-archive.org/</ext-link>. EGA data are available and may be obtained through controlled access at <ext-link xlink:href="https://ega-archive.org/access/request-data/how-to-request-data/" ext-link-type="uri">https://ega-archive.org/access/request-data/how-to-request-data/</ext-link> with restricted use to approved investigators. </p></sec></ack><sec sec-type="supplementary-material"><title>Supplementary Materials</title><sec><title>The PDF file includes:</title><supplementary-material position="float" content-type="local-data"><caption><p>Figs. S1 to S24</p><p>Legends for tables S1 to S6</p></caption><media xlink:href="sciadv.ads5002_sm.pdf"/></supplementary-material></sec><sec><title>Other Supplementary Material for this manuscript includes the following:</title><supplementary-material position="float" content-type="local-data"><caption><p>Tables S1 to S6</p></caption><media xlink:href="sciadv.ads5002_tables_s1_to_s6.zip"/></supplementary-material></sec></sec><ref-list><title>REFERENCES AND NOTES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Sung</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ferlay</surname></string-name>, <string-name><given-names>R. L.</given-names>
<surname>Siegel</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Laversanne</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Soerjomataram</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Jemal</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Bray</surname></string-name></person-group>, 
<article-title>Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source>
<volume>71</volume>, 
<fpage>209</fpage>&#x02013;<lpage>249</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Rishi</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Goggins</surname></string-name>, <string-name><given-names>L. D.</given-names>
<surname>Wood</surname></string-name>, <string-name><given-names>R. H.</given-names>
<surname>Hruban</surname></string-name></person-group>, 
<article-title>Pathological and molecular evaluation of pancreatic neoplasms</article-title>. <source>Semin. Oncol.</source>
<volume>42</volume>, 
<fpage>28</fpage>&#x02013;<lpage>39</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25726050</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. L.</given-names>
<surname>Siegel</surname></string-name>, <string-name><given-names>K. D.</given-names>
<surname>Miller</surname></string-name>, <string-name><given-names>N. S.</given-names>
<surname>Wagle</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Jemal</surname></string-name></person-group>, 
<article-title>Cancer statistics, 2023</article-title>. <source>CA Cancer J. Clin.</source>
<volume>73</volume>, 
<fpage>17</fpage>&#x02013;<lpage>48</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">36633525</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Ducreux</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Cuhna</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Caramella</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hollebecque</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Burtin</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Go&#x000e9;r&#x000e9;</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Seufferlein</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Haustermans</surname></string-name>, <string-name><given-names>J. L. V.</given-names>
<surname>Laethem</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Conroy</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Arnold</surname></string-name>, <collab>ESMO Guidelines Committee</collab></person-group>, 
<article-title>Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</article-title>. <source>Ann. Oncol.</source>
<volume>26</volume>, 
<fpage>v56</fpage>&#x02013;<lpage>v68</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26314780</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. Q.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>M.-F.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>H.-L.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Shang</surname></string-name>, <string-name><given-names>J. K.</given-names>
<surname>Das</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Song</surname></string-name></person-group>, 
<article-title>Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma</article-title>. <source>Mol. Cancer</source>
<volume>19</volume>, 
<fpage>32</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32061257</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Lytle</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Parpart-Li</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nesselbush</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Shukla</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chesnick</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kadan</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Papp</surname></string-name>, <string-name><given-names>K. G.</given-names>
<surname>Galens</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Kann</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Sausen</surname></string-name>, <string-name><given-names>S. V.</given-names>
<surname>Angiuoli</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Diaz</surname>
<suffix>Jr.</suffix></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Personalized genomic analyses for cancer mutation discovery and interpretation</article-title>. <source>Sci. Transl. Med.</source>
<volume>7</volume>, 
<fpage>283ra53</fpage> (<year>2015</year>).</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I. M.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Theile</surname></string-name>, <string-name><given-names>J. X.</given-names>
<surname>Hjaltelin</surname></string-name>, <string-name><given-names>S. I.</given-names>
<surname>Novitski</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Brunak</surname></string-name>, <string-name><given-names>J. P.</given-names>
<surname>Hasselby</surname></string-name>, <string-name><given-names>G. L.</given-names>
<surname>Willemoe</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Lorentzen</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>B. V.</given-names>
<surname>Jensen</surname></string-name>, <string-name><given-names>E. E.</given-names>
<surname>Wilken</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Geertsen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Behrens</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Nolsoe</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Hermann</surname></string-name>, <string-name><given-names>I. M.</given-names>
<surname>Svane</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Nielsen</surname></string-name></person-group>, 
<article-title>Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)</article-title>. <source>J. Clin. Oncol.</source>
<volume>40</volume>, 
<fpage>3180</fpage>&#x02013;<lpage>3189</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35476508</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. R.</given-names>
<surname>Brahmer</surname></string-name>, <string-name><given-names>S. S.</given-names>
<surname>Tykodi</surname></string-name>, <string-name><given-names>L. Q. M.</given-names>
<surname>Chow</surname></string-name>, <string-name><given-names>W.-J.</given-names>
<surname>Hwu</surname></string-name>, <string-name><given-names>S. L.</given-names>
<surname>Topalian</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Hwu</surname></string-name>, <string-name><given-names>C. G.</given-names>
<surname>Drake</surname></string-name>, <string-name><given-names>L. H.</given-names>
<surname>Camacho</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kauh</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Odunsi</surname></string-name>, <string-name><given-names>H. C.</given-names>
<surname>Pitot</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Hamid</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Bhatia</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Martins</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Eaton</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Salay</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Alaparthy</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>Grosso</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Korman</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Parker</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Agrawal</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Goldberg</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Pardoll</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Gupta</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Wigginton</surname></string-name></person-group>, 
<article-title>Safety and activity of anti&#x02013;PD-L1 antibody in patients with advanced cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>366</volume>, 
<fpage>2455</fpage>&#x02013;<lpage>2465</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22658128</pub-id>
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>Akhuba</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Tigai</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Shek</surname></string-name></person-group>, 
<article-title>Where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma: A synopsis of clinical outcomes</article-title>. <source>Biomedicines</source>
<volume>10</volume>, 
<fpage>3196</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36551952</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. N.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>J. V.</given-names>
<surname>Thomas</surname></string-name>, <string-name><given-names>M. E.</given-names>
<surname>Lockhart</surname></string-name>, <string-name><given-names>L. L.</given-names>
<surname>Berland</surname></string-name>, <string-name><given-names>D. E.</given-names>
<surname>Morgan</surname></string-name></person-group>, 
<article-title>Single-source dual-energy spectral multidetector CT of pancreatic adenocarcinoma: Optimization of energy level viewing significantly increases lesion contrast</article-title>. <source>Clin. Radiol.</source>
<volume>68</volume>, 
<fpage>148</fpage>&#x02013;<lpage>154</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">22889459</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. A.</given-names>
<surname>Overbeek</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Goggins</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Dbouk</surname></string-name>, <string-name><given-names>I. J. M.</given-names>
<surname>Levink</surname></string-name>, <string-name><given-names>B. D. M.</given-names>
<surname>Koopmann</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chuidian</surname></string-name>, <string-name><given-names>I. C. A. W.</given-names>
<surname>Konings</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Paiella</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Earl</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Fockens</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Gress</surname></string-name>, <string-name><given-names>M. G. E. M.</given-names>
<surname>Ausems</surname></string-name>, <string-name><given-names>J.-W.</given-names>
<surname>Poley</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Thosani</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Half</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Lachter</surname></string-name>, <string-name><given-names>E. M.</given-names>
<surname>Stoffel</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Kwon</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Stoita</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Kastrinos</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Lucas</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Syngal</surname></string-name>, <string-name><given-names>R. E.</given-names>
<surname>Brand</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chak</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Carrato</surname></string-name>, <string-name><given-names>F. P.</given-names>
<surname>Vleggaar</surname></string-name>, <string-name><given-names>D. K.</given-names>
<surname>Bartsch</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>van Hooft</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Cahen</surname></string-name>, <string-name><given-names>M. I.</given-names>
<surname>Canto</surname></string-name>, <string-name><given-names>M. J.</given-names>
<surname>Bruno</surname></string-name>, <collab>International Cancer of the Pancreas Screening Consortium</collab></person-group>, 
<article-title>Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals</article-title>. <source>Gastroenterology</source>
<volume>162</volume>, 
<fpage>772</fpage>&#x02013;<lpage>785.e4</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34678218</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. M.</given-names>
<surname>Jang</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>Y. K.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>K. D.</given-names>
<surname>Song</surname></string-name>, <string-name><given-names>S. J.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Choi</surname></string-name></person-group>, 
<article-title>Missed pancreatic ductal adenocarcinoma: Assessment of early imaging findings on prediagnostic magnetic resonance imaging</article-title>. <source>Eur. J. Radiol.</source>
<volume>84</volume>, 
<fpage>1473</fpage>&#x02013;<lpage>1479</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26032128</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Zang</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Jin</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Shahatiaili</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Du</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jia</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Zhuang</surname></string-name></person-group>, 
<article-title>Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial</article-title>. <source>J. Pathol.</source>
<volume>261</volume>, 
<fpage>198</fpage>&#x02013;<lpage>209</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37584165</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. J.</given-names>
<surname>Grossberg</surname></string-name>, <string-name><given-names>L. C.</given-names>
<surname>Chu</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Deig</surname></string-name>, <string-name><given-names>E. K.</given-names>
<surname>Fishman</surname></string-name>, <string-name><given-names>W. L.</given-names>
<surname>Hwang</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Maitra</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Marks</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mehta</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Nabavizadeh</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Simeone</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Weekes</surname></string-name>, <string-name><given-names>C. R.</given-names>
<surname>Thomas</surname>
<suffix>Jr.</suffix></string-name></person-group>, 
<article-title>Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma</article-title>. <source>CA Cancer J. Clin.</source>
<volume>70</volume>, 
<fpage>375</fpage>&#x02013;<lpage>403</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32683683</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. J.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>K. W.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Pyo</surname></string-name>, <string-name><given-names>C. H.</given-names>
<surname>Suh</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Yoon</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Hatabu</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nishino</surname></string-name></person-group>, 
<article-title>Incidence of pseudoprogression during Immune checkpoint inhibitor therapy for solid tumors: A systematic review and meta-analysis</article-title>. <source>Radiology</source>
<volume>297</volume>, 
<fpage>87</fpage>&#x02013;<lpage>96</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32749204</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Azizian</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>R&#x000fc;hlmann</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Krause</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Bernhardt</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Jo</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>K&#x000f6;nig</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Klei&#x000df;</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leha</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ghadimi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gaedcke</surname></string-name></person-group>, 
<article-title>CA19-9 for detecting recurrence of pancreatic cancer</article-title>. <source>Sci. Rep.</source>
<volume>10</volume>, 
<fpage>1332</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31992753</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>P. B.</given-names>
<surname>Bach</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Lau</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Cell-free DNA approaches for cancer early detection and interception</article-title>. <source>J. Immunother. Cancer</source>
<volume>11</volume>, 
<fpage>e006013</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37696619</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Sausen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Leary</surname></string-name>, <string-name><given-names>M. T.</given-names>
<surname>Barrett</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Parpart-Li</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>Q. K.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>O&#x02019;Dwyer</surname></string-name>, <string-name><given-names>P. J.</given-names>
<surname>Allen</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Eshleman</surname></string-name>, <string-name><given-names>C. B.</given-names>
<surname>Thompson</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Klimstra</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Linehan</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Maitra</surname></string-name>, <string-name><given-names>R. H.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Diaz</surname></string-name>, <string-name><given-names>D. D. V.</given-names>
<surname>Hoff</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Drebin</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients</article-title>. <source>Nat. Commun.</source>
<volume>6</volume>, 
<fpage>7686</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26154128</pub-id>
</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. J.</given-names>
<surname>Leary</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Kinde</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Diehl</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Schmidt</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Clouser</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Duncan</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Antipova</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>McKernan</surname></string-name>, <string-name><given-names>F. M. D. L.</given-names>
<surname>Vega</surname></string-name>, <string-name><given-names>K. W.</given-names>
<surname>Kinzler</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Vogelstein</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Diaz</surname>
<suffix>Jr.</suffix></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Development of personalized tumor biomarkers using massively parallel sequencing</article-title>. <source>Sci. Transl. Med.</source>
<volume>2</volume>, 
<fpage>20ra14</fpage> (<year>2010</year>).</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V. A.</given-names>
<surname>Adalsteinsson</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ha</surname></string-name>, <string-name><given-names>S. S.</given-names>
<surname>Freeman</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Choudhury</surname></string-name>, <string-name><given-names>D. G.</given-names>
<surname>Stover</surname></string-name>, <string-name><given-names>H. A.</given-names>
<surname>Parsons</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Gydush</surname></string-name>, <string-name><given-names>S. C.</given-names>
<surname>Reed</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Rotem</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Rhoades</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Loginov</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Livitz</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Rosebrock</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Leshchiner</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Stewart</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rosenberg</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Francis</surname></string-name>, <string-name><given-names>C.-Z.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Cohen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Oh</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Ding</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Polak</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Lloyd</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Mahmud</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Helvie</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Merrill</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Santiago</surname></string-name>, <string-name><given-names>E. P.</given-names>
<surname>O&#x02019;Connor</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Jeong</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Leeson</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Barry</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>Kramkowski</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Polacek</surname></string-name>, <string-name><given-names>J. G.</given-names>
<surname>Lohr</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Schleicher</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Lipscomb</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Saltzman</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Oliver</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Marini</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Waks</surname></string-name>, <string-name><given-names>L. C.</given-names>
<surname>Harshman</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Tolaney</surname></string-name>, <string-name><given-names>E. M. V.</given-names>
<surname>Allen</surname></string-name>, <string-name><given-names>E. P.</given-names>
<surname>Winer</surname></string-name>, <string-name><given-names>N. U.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nakabayashi</surname></string-name>, <string-name><given-names>M.-E.</given-names>
<surname>Taplin</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Johannessen</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Garraway</surname></string-name>, <string-name><given-names>T. R.</given-names>
<surname>Golub</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Boehm</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Wagle</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Getz</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Love</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Meyerson</surname></string-name></person-group>, 
<article-title>Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, 
<fpage>1324</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29109393</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Sogbe</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Bilbao</surname></string-name>, <string-name><given-names>F. P.</given-names>
<surname>Marchese</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zazpe</surname></string-name>, <string-name><given-names>A. D.</given-names>
<surname>Vito</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pozuelo</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>D&#x02019;Avola</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>I&#x000f1;arrairaegui</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Berasain</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Arechederra</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Argemi</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Sangro</surname></string-name></person-group>, 
<article-title>Prognostic value of ultra-low-pass whole-cenome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment</article-title>. <source>Clin. Mol. Hepatol.</source>
<volume>30</volume>, 
<fpage>177</fpage>&#x02013;<lpage>190</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">38163441</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Zviran</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Schulman</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Shah</surname></string-name>, <string-name><given-names>S. T. K.</given-names>
<surname>Hill</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Deochand</surname></string-name>, <string-name><given-names>C. C.</given-names>
<surname>Khamnei</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Maloney</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Liao</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Widman</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Wong</surname></string-name>, <string-name><given-names>M. K.</given-names>
<surname>Callahan</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ha</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Reed</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Rotem</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Frederick</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Sharova</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Miao</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Gydush</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Rhoades</surname></string-name>, <string-name><given-names>K. Y.</given-names>
<surname>Huang</surname></string-name>, <string-name><given-names>N. D.</given-names>
<surname>Omans</surname></string-name>, <string-name><given-names>P. O.</given-names>
<surname>Bolan</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Lipsky</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Ang</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Malbari</surname></string-name>, <string-name><given-names>C. F.</given-names>
<surname>Spinelli</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kazancioglu</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Runnels</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Fennessey</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Stolte</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Gaiti</surname></string-name>, <string-name><given-names>G. G.</given-names>
<surname>Inghirami</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adalsteinsson</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Houck-Loomis</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ishii</surname></string-name>, <string-name><given-names>J. D.</given-names>
<surname>Wolchok</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Boland</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Robine</surname></string-name>, <string-name><given-names>N. K.</given-names>
<surname>Altorki</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Landau</surname></string-name></person-group>, 
<article-title>Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring</article-title>. <source>Nat. Med.</source>
<volume>26</volume>, 
<fpage>1114</fpage>&#x02013;<lpage>1124</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32483360</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Qian</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Ma</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Liang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bai</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Fan</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Hao</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Gao</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Bai</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Dou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Jiang</surname></string-name>, <string-name><given-names>Q.</given-names>
<surname>Xia</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Rao</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Xia</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Shang</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Gao</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Xie</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Gao</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Liu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Jiang</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Niu</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Hou</surname></string-name></person-group>, 
<article-title>Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures</article-title>. <source>J. Hepatol.</source>
<volume>79</volume>, 
<fpage>933</fpage>&#x02013;<lpage>944</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37302583</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Gogl</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Zambo</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Kostmann</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cousido-Siah</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Morlet</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Durbesson</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Negroni</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Eberling</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Jan&#x000e9;</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Nomin&#x000e9;</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Zeke</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>&#x000d8;stergaard</surname></string-name>, <string-name><given-names>&#x000c9;.</given-names>
<surname>Monsellier</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Vincentelli</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Trav&#x000e9;</surname></string-name></person-group>, 
<article-title>Quantitative fragmentomics allow affinity mapping of interactomes</article-title>. <source>Nat. Commun.</source>
<volume>13</volume>, 
<fpage>5472</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36115835</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Mathios</surname></string-name>, <string-name><given-names>Z. H.</given-names>
<surname>Foda</surname></string-name>, <string-name><given-names>A. V.</given-names>
<surname>Annapragada</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>E. J.</given-names>
<surname>Chiao</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Ferreira</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Mazzilli</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Billatos</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Spira</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Zaidi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Mueller</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer</article-title>. <source>Nat. Genet.</source>
<volume>55</volume>, 
<fpage>1301</fpage>&#x02013;<lpage>1310</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37500728</pub-id>
</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Fiksel</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>S. &#x000d8;.</given-names>
<surname>Jensen</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>D. N.</given-names>
<surname>Palsgrove</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Forde</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Naidoo</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Marrone</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Brahmer</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Woodward</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Husain</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>van Rooijen</surname></string-name>, <string-name><given-names>M.-B. W.</given-names>
<surname>&#x000d8;rntoft</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>C. J. H.</given-names>
<surname>van de Velde</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Verheij</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Cats</surname></string-name>, <string-name><given-names>C. J. A.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>G. R.</given-names>
<surname>Vink</surname></string-name>, <string-name><given-names>N. C. T.</given-names>
<surname>van Grieken</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Koopman</surname></string-name>, <string-name><given-names>R. J. A.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>H. J.</given-names>
<surname>Nielsen</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Genome-wide cell-free DNA fragmentation in patients with cancer</article-title>. <source>Nature</source>
<volume>570</volume>, 
<fpage>385</fpage>&#x02013;<lpage>389</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31142840</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Mathios</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>K. R.</given-names>
<surname>Larsen</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Ferreira</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>J. Y.</given-names>
<surname>Chiao</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Noe</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Arun</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>A. V.</given-names>
<surname>Annapragada</surname></string-name>, <string-name><given-names>S. &#x000d8;.</given-names>
<surname>Jensen</surname></string-name>, <string-name><given-names>M.-B. W.</given-names>
<surname>&#x000d8;rntoft</surname></string-name>, <string-name><given-names>A. H.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Carvalho</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>de Wit</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Maddala</surname></string-name>, <string-name><given-names>K. C.</given-names>
<surname>Fang</surname></string-name>, <string-name><given-names>A.-R.</given-names>
<surname>Hartman</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Forde</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Brahmer</surname></string-name>, <string-name><given-names>R. J. A.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>H. J.</given-names>
<surname>Nielsen</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Mellemgaard</surname></string-name>, <string-name><given-names>S. E.</given-names>
<surname>Bojesen</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Detection and characterization of lung cancer using cell-free DNA fragmentomes</article-title>. <source>Nat. Commun.</source>
<volume>12</volume>, 
<fpage>5060</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34417454</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Lumbard</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>Keefer</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>van&#x02019;t erve</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chesnick</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Butler</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rongione</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name></person-group>, 
<article-title>Abstract 2224: DELFI as a real-time treatment response assessment for patients with cancer</article-title>. <source>Cancer Res.</source>
<volume>82</volume>, 
<fpage>2224</fpage> (<year>2022</year>).</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Alipanahi</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>van &#x02018;t Erve</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Lumbard</surname></string-name>, <string-name><given-names>L. K.</given-names>
<surname>Millberg</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Skidmore</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rinaldi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Tom</surname></string-name>, <string-name><given-names>C. J. A.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name></person-group>, 
<article-title>Abstract 5714: Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer</article-title>. <source>Cancer Res.</source>
<volume>83</volume>, 
<fpage>5714</fpage> (<year>2023</year>).</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z. L.</given-names>
<surname>Skidmore</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>van &#x02018;t Erve</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Lumbard</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Alipanahi</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Keefer</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rinaldi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Tom</surname></string-name>, <string-name><given-names>C. J. A.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name></person-group>, 
<article-title>Cell-free DNA fragmentation profiling for therapeutic response monitoring in metastatic colorectal cancer</article-title>. <source>J. Clin. Oncol.</source>
<volume>41</volume>, 
<fpage>e15664</fpage> (<year>2023</year>).</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I.</given-names>
<surname>van &#x02018;t Erve</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Alipanahi</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Lumbard</surname></string-name>, <string-name><given-names>Z. L.</given-names>
<surname>Skidmore</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rinaldi</surname></string-name>, <string-name><given-names>L. K.</given-names>
<surname>Millberg</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Chesnick</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Portwood</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Peters</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Bolhuis</surname></string-name>, <string-name><given-names>C. J. A.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Tom</surname></string-name>, <string-name><given-names>P. B.</given-names>
<surname>Bach</surname></string-name>, <string-name><given-names>N. C.</given-names>
<surname>Dracopoli</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name>, <string-name><given-names>R. J. A.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name></person-group>, 
<article-title>Cancer treatment monitoring using cell-free DNA fragmentomes</article-title>. <source>Nat. Commun.</source>
<volume>15</volume>, 
<fpage>8801</fpage> (<year>2024</year>).<pub-id pub-id-type="pmid">39433569</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. V.</given-names>
<surname>Annapragada</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Cherry</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Mathios</surname></string-name>, <string-name><given-names>Z. H.</given-names>
<surname>Foda</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Genome-wide repeat landscapes in cancer and cell-free DNA</article-title>. <source>Sci. Transl. Med.</source>
<volume>16</volume>, 
<fpage>eadj9283</fpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38478628</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>I. M.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Theile</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Dajani</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Lorentzen</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Zimmers</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Nielsen</surname></string-name></person-group>, 
<article-title>Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)</article-title>. <source>J. Clin. Oncol.</source>
<volume>41</volume>, 
<fpage>4147</fpage> (<year>2023</year>).</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Powles</surname></string-name>, <string-name><given-names>Z. J.</given-names>
<surname>Assaf</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Davarpanah</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Banchereau</surname></string-name>, <string-name><given-names>B. E.</given-names>
<surname>Szabados</surname></string-name>, <string-name><given-names>K. C.</given-names>
<surname>Yuen</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Grivas</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Hussain</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Oudard</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Gschwend</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Albers</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Castellano</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Nishiyama</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Daneshmand</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Sharma</surname></string-name>, <string-name><given-names>B. G.</given-names>
<surname>Zimmermann</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Sethi</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Aleshin</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Perdicchio</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Zhang</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Shames</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Degaonkar</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Carter</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Bais</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Bellmunt</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Mariathasan</surname></string-name></person-group>, 
<article-title>ctDNA guiding adjuvant immunotherapy in urothelial carcinoma</article-title>. <source>Nature</source>
<volume>595</volume>, 
<fpage>432</fpage>&#x02013;<lpage>437</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34135506</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>P. M.</given-names>
<surname>Forde</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Naidoo</surname></string-name>, <string-name><given-names>K. A.</given-names>
<surname>Marrone</surname></string-name>, <string-name><given-names>I. K. A.</given-names>
<surname>Sivakumar</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rosner</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>K. N.</given-names>
<surname>Smith</surname></string-name>, <string-name><given-names>T. R.</given-names>
<surname>Cottrell</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Rhymee</surname></string-name>, <string-name><given-names>D. N.</given-names>
<surname>Palsgrove</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Hann</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Levy</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Feliciano</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Georgiades</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Verde</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Illei</surname></string-name>, <string-name><given-names>Q. K.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Gabrielson</surname></string-name>, <string-name><given-names>M. V.</given-names>
<surname>Brock</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Isbell</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Sauter</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Taube</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Karchin</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Pardoll</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Chaft</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Hellmann</surname></string-name>, <string-name><given-names>J. R.</given-names>
<surname>Brahmer</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Dynamics of tumor and immune responses during immune checkpoint blockade in non&#x02013;small cell lung cancer</article-title>. <source>Cancer Res.</source>
<volume>79</volume>, 
<fpage>1214</fpage>&#x02013;<lpage>1225</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30541742</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas Research Network</collab></person-group>, 
<article-title>Integrated genomic characterization of pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Cell.</source>
<volume>32</volume>, 
<fpage>185</fpage>&#x02013;<lpage>203.e13</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28810144</pub-id>
</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. J.</given-names>
<surname>Landrum</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>G. R.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Jang</surname></string-name>, <string-name><given-names>W. S.</given-names>
<surname>Rubinstein</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Church</surname></string-name>, <string-name><given-names>D. R.</given-names>
<surname>Maglott</surname></string-name></person-group>, 
<article-title>ClinVar: Public archive of relationships among sequence variation and human phenotype</article-title>. <source>Nucleic Acids Res.</source>
<volume>42</volume>, 
<fpage>D980</fpage>&#x02013;<lpage>D985</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24234437</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. A.</given-names>
<surname>Thompson</surname></string-name>, <string-name><given-names>A. B.</given-names>
<surname>Spurdle</surname></string-name>, <string-name><given-names>J.-P.</given-names>
<surname>Plazzer</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Greenblatt</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Akagi</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Al-Mulla</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Bapat</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Bernstein</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Capell&#x000e1;</surname></string-name>, <string-name><given-names>J. T.</given-names>
<surname>den Dunnen</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>du Sart</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Fabre</surname></string-name>, <string-name><given-names>M. P.</given-names>
<surname>Farrell</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Farrington</surname></string-name>, <string-name><given-names>I. M.</given-names>
<surname>Frayling</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Frebourg</surname></string-name>, <string-name><given-names>D. E.</given-names>
<surname>Goldgar</surname></string-name>, <string-name><given-names>C. D.</given-names>
<surname>Heinen</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Holinski-Feder</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kohonen-Corish</surname></string-name>, <string-name><given-names>K. L.</given-names>
<surname>Robinson</surname></string-name>, <string-name><given-names>S. Y.</given-names>
<surname>Leung</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Martins</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Moller</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Morak</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nystrom</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Peltomaki</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Pineda</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Qi</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Ramesar</surname></string-name>, <string-name><given-names>L. J.</given-names>
<surname>Rasmussen</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Royer-Pokora</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Scott</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Sijmons</surname></string-name>, <string-name><given-names>S. V.</given-names>
<surname>Tavtigian</surname></string-name>, <string-name><given-names>C. M.</given-names>
<surname>Tops</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Weber</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wijnen</surname></string-name>, <string-name><given-names>M. O.</given-names>
<surname>Woods</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Macrae</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Genuardi</surname></string-name>, <collab>InSiGHT</collab></person-group>, 
<article-title>Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database</article-title>. <source>Nat. Genet.</source>
<volume>46</volume>, 
<fpage>107</fpage>&#x02013;<lpage>115</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24362816</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z.</given-names>
<surname>Sondka</surname></string-name>, <string-name><given-names>N. B.</given-names>
<surname>Dhir</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Carvalho-Silva</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jupe</surname></string-name>, <string-name><surname>Madhumita</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>McLaren</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Starkey</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wilding</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ahmed</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Argasinska</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Beare</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Chawla</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Duke</surname></string-name>, <string-name><given-names>I.</given-names>
<surname>Fasanella</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Neogi</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Haller</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Hetenyi</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Hodges</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Holmes</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Lyne</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Maurel</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Nair</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Pedro</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Sangrador-Vegas</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Schuilenburg</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Sheard</surname></string-name>, <string-name><given-names>S. Y.</given-names>
<surname>Yong</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Teague</surname></string-name></person-group>, 
<article-title>COSMIC: A curated database of somatic variants and clinical data for cancer</article-title>. <source>Nucleic Acids Res.</source>
<volume>52</volume>, 
<fpage>D1210</fpage>&#x02013;<lpage>D1217</lpage> (<year>2024</year>).<pub-id pub-id-type="pmid">38183204</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Gale</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Heider</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ruiz-Valdepenas</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Hackinger</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Perry</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Marsico</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Rundell</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Wulff</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Sharma</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Knock</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Castedo</surname></string-name>, <string-name><given-names>W.</given-names>
<surname>Cooper</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zhao</surname></string-name>, <string-name><given-names>C. G.</given-names>
<surname>Smith</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Garg</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Anand</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Howarth</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Gilligan</surname></string-name>, <string-name><given-names>S. V.</given-names>
<surname>Harden</surname></string-name>, <string-name><given-names>D. M.</given-names>
<surname>Rassl</surname></string-name>, <string-name><given-names>R. C.</given-names>
<surname>Rintoul</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Rosenfeld</surname></string-name></person-group>, 
<article-title>Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer</article-title>. <source>Ann. Oncol.</source>
<volume>33</volume>, 
<fpage>500</fpage>&#x02013;<lpage>510</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35306155</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Abbosh</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Frankell</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Harrison</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Kisistok</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Garnett</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Johnson</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Veeriah</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Moreau</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Chesh</surname></string-name>, <string-name><given-names>T. L.</given-names>
<surname>Chaunzwa</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Weiss</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Schroeder</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Grigoriadis</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Shahpurwalla</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Litchfield</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Puttick</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Biswas</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Karasaki</surname></string-name>, <string-name><given-names>J. R. M.</given-names>
<surname>Black</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Mart&#x000ed;nez-Ruiz</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Bakir</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Pich</surname></string-name>, <string-name><given-names>T. B. K.</given-names>
<surname>Watkins</surname></string-name>, <string-name><given-names>E. L.</given-names>
<surname>Lim</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Huebner</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Moore</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Godin-Heymann</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Hernault</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Bye</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Odell</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Kalavakur</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Gomes</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Patel</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Manzano</surname></string-name>, <string-name><given-names>C. T.</given-names>
<surname>Hiley</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Carey</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>D. E.</given-names>
<surname>Cook</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Hodgson</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Stetson</surname></string-name>, <string-name><given-names>J. C.</given-names>
<surname>Barrett</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Kortlever</surname></string-name>, <string-name><given-names>G. I.</given-names>
<surname>Evan</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hackshaw</surname></string-name>, <string-name><given-names>R. D.</given-names>
<surname>Daber</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Shaw</surname></string-name>, <string-name><given-names>H. J. W. L.</given-names>
<surname>Aerts</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Licon</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Stahl</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Jamal-Hanjani</surname></string-name>, <collab>TRACERx Consortium</collab>, <string-name><given-names>N. J.</given-names>
<surname>Birkbak</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Granahan</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Swanton</surname></string-name></person-group>, 
<article-title>Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA</article-title>. <source>Nature</source>
<volume>616</volume>, 
<fpage>553</fpage>&#x02013;<lpage>562</lpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37055640</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. L.</given-names>
<surname>Torre</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Nigri</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Cavallini</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Mercantini</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ziparo</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Ramacciato</surname></string-name></person-group>, 
<article-title>The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma</article-title>. <source>Ann. Surg. Oncol.</source>
<volume>19</volume>, 
<fpage>2917</fpage>&#x02013;<lpage>2923</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22488099</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. H.</given-names>
<surname>Yu</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Ozer</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Cockrum</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Surinach</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>B. C.</given-names>
<surname>Chu</surname></string-name></person-group>, 
<article-title>Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Med.</source>
<volume>10</volume>, 
<fpage>8934</fpage>&#x02013;<lpage>8943</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34811961</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Z. H.</given-names>
<surname>Foda</surname></string-name>, <string-name><given-names>A. V.</given-names>
<surname>Annapragada</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Boyapati</surname></string-name>, <string-name><given-names>D. C.</given-names>
<surname>Bruhm</surname></string-name>, <string-name><given-names>N. A.</given-names>
<surname>Vulpescu</surname></string-name>, <string-name><given-names>J. E.</given-names>
<surname>Medina</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Mathios</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>H. T.</given-names>
<surname>Luu</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Goggins</surname></string-name>, <string-name><given-names>R. A.</given-names>
<surname>Anders</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>S. H.</given-names>
<surname>Mehta</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Thomas</surname></string-name>, <string-name><given-names>G. D.</given-names>
<surname>Kirk</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Detecting liver cancer using cell-free DNA fragmentomes</article-title>. <source>Cancer Discov.</source>
<volume>13</volume>, 
<fpage>616</fpage>&#x02013;<lpage>631</lpage> (<year>2022</year>).</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Seshan</surname></string-name></person-group>, 
<article-title>FACETS: Allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, 
<fpage>e131</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27270079</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Harada</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Chelala</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Bhakta</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Chaplin</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Caulee</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Baril</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Young</surname></string-name>, <string-name><given-names>N. R.</given-names>
<surname>Lemoine</surname></string-name></person-group>, 
<article-title>Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays</article-title>. <source>Oncogene</source>
<volume>27</volume>, 
<fpage>1951</fpage>&#x02013;<lpage>1960</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">17952125</pub-id>
</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.-P.</given-names>
<surname>Fortin</surname></string-name>, <string-name><given-names>K. D.</given-names>
<surname>Hansen</surname></string-name></person-group>, 
<article-title>Reconstructing A/B compartments as revealed by Hi-C using long-range correlations in epigenetic data</article-title>. <source>Genome Biol.</source>
<volume>16</volume>, 
<fpage>180</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26316348</pub-id>
</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>U. K.</given-names>
<surname>Ballehaninna</surname></string-name>, <string-name><given-names>R. S.</given-names>
<surname>Chamberlain</surname></string-name></person-group>, 
<article-title>The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal</article-title>. <source>J. Gastrointest. Oncol.</source>
<volume>3</volume>, 
<fpage>105</fpage>&#x02013;<lpage>119</lpage> (<year>2011</year>).</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Abbosh</surname></string-name>, <string-name><given-names>N. J.</given-names>
<surname>Birkbak</surname></string-name>, <string-name><given-names>G. A.</given-names>
<surname>Wilson</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Jamal-Hanjani</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Constantin</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Salari</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Quesne</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Moore</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Veeriah</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Rosenthal</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Marafioti</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Kirkizlar</surname></string-name>, <string-name><given-names>T. B. K.</given-names>
<surname>Watkins</surname></string-name>, <string-name><given-names>N. M.</given-names>
<surname>Granahan</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Ward</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Martinson</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Fraioli</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Bakir</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Gr&#x000f6;nroos</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Zambrana</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Endozo</surname></string-name>, <string-name><given-names>W. L.</given-names>
<surname>Bi</surname></string-name>, <string-name><given-names>F. M.</given-names>
<surname>Fennessy</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Sponer</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Johnson</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Laycock</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Shafi</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Czyzewska-Khan</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Rowan</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Chambers</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Matthews</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Turajlic</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hiley</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>M. D.</given-names>
<surname>Forster</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Ahmad</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Falzon</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Borg</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Lawrence</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Hayward</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kolvekar</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Panagiotopoulos</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Janes</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Thakrar</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ahmed</surname></string-name>, <string-name><given-names>F.</given-names>
<surname>Blackhall</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Summers</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Hafez</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Naik</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ganguly</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Kareht</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Shah</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Joseph</surname></string-name>, <string-name><given-names>A. M.</given-names>
<surname>Quinn</surname></string-name>, <string-name><given-names>P. A.</given-names>
<surname>Crosbie</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Naidu</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Middleton</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Langman</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Trotter</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nicolson</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Remmen</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kerr</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Chetty</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Gomersall</surname></string-name>, <string-name><given-names>D. A.</given-names>
<surname>Fennell</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Nakas</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Rathinam</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Anand</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Khan</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Russell</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Ezhil</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Ismail</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Irvin-Sellers</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Prakash</surname></string-name>, <string-name><given-names>J. F.</given-names>
<surname>Lester</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Kornaszewska</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Attanoos</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Adams</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Davies</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Oukrif</surname></string-name>, <string-name><given-names>A. U.</given-names>
<surname>Akarca</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Hartley</surname></string-name>, <string-name><given-names>H. L.</given-names>
<surname>Lowe</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Lock</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Iles</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Bell</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Ngai</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Elgar</surname></string-name>, <string-name><given-names>Z.</given-names>
<surname>Szallasi</surname></string-name>, <string-name><given-names>R. F.</given-names>
<surname>Schwarz</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Herrero</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Stewart</surname></string-name>, <string-name><given-names>S. A.</given-names>
<surname>Quezada</surname></string-name>, <string-name><given-names>K. S.</given-names>
<surname>Peggs</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Van Loo</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Dive</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Rabinowitz</surname></string-name>, <string-name><given-names>H. J. W. L.</given-names>
<surname>Aerts</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Hackshaw</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Shaw</surname></string-name>, <string-name><given-names>B. G.</given-names>
<surname>Zimmermann</surname></string-name>, <collab>TRACERx consortium</collab>, <collab>PEACE consortium</collab>, <string-name><given-names>C.</given-names>
<surname>Swanton</surname></string-name></person-group>, 
<article-title>Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution</article-title>. <source>Nature</source>
<volume>545</volume>, 
<fpage>446</fpage>&#x02013;<lpage>451</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28445469</pub-id>
</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. I.</given-names>
<surname>Labidi-Galy</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Papp</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Hallberg</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Niknafs</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Noe</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Bhattacharya</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Novak</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>C. A.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>M. S.</given-names>
<surname>Hirsch</surname></string-name>, <string-name><given-names>D. I.</given-names>
<surname>Lin</surname></string-name>, <string-name><given-names>L.</given-names>
<surname>Schwartz</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Maire</surname></string-name>, <string-name><given-names>J.-C.</given-names>
<surname>Tille</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Bowden</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Ayhan</surname></string-name>, <string-name><given-names>L. D.</given-names>
<surname>Wood</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Kurman</surname></string-name>, <string-name><given-names>T.-L.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>I.-M.</given-names>
<surname>Shih</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Karchin</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Drapkin</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>High grade serous ovarian carcinomas originate in the fallopian tube</article-title>. <source>Nat. Commun.</source>
<volume>8</volume>, 
<fpage>1093</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29061967</pub-id>
</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Phallen</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Sausen</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Adleff</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Leal</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Hruban</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>White</surname></string-name>, <string-name><given-names>V.</given-names>
<surname>Anagnostou</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Fiksel</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cristiano</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Papp</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Speir</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Reinert</surname></string-name>, <string-name><given-names>M.-B. W.</given-names>
<surname>Orntoft</surname></string-name>, <string-name><given-names>B. D.</given-names>
<surname>Woodward</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Murphy</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Parpart-Li</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Riley</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nesselbush</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Sengamalay</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Georgiadis</surname></string-name>, <string-name><given-names>Q. K.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>M. R.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>F. V.</given-names>
<surname>Mortensen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Huiskens</surname></string-name>, <string-name><given-names>C.</given-names>
<surname>Punt</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>van Grieken</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Fijneman</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Meijer</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Husain</surname></string-name>, <string-name><given-names>R. B.</given-names>
<surname>Scharpf</surname></string-name>, <string-name><given-names>L. A.</given-names>
<surname>DiazJr</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Angiuoli</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>&#x000d8;rntoft</surname></string-name>, <string-name><given-names>H. J.</given-names>
<surname>Nielsen</surname></string-name>, <string-name><given-names>C. L.</given-names>
<surname>Andersen</surname></string-name>, <string-name><given-names>V. E.</given-names>
<surname>Velculescu</surname></string-name></person-group>, 
<article-title>Direct detection of early-stage cancers using circulating tumor DNA</article-title>. <source>Sci. Transl. Med.</source>
<volume>9</volume>, 
<fpage>eaan2415</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28814544</pub-id>
</mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Zhou</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Gu</surname></string-name></person-group>, 
<article-title>fastp: An ultra-fast all-in-one FASTQ preprocessor</article-title>. <source>Bioinformatics</source>
<volume>34</volume>, 
<fpage>i884</fpage>&#x02013;<lpage>i890</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30423086</pub-id>
</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Langmead</surname></string-name>, <string-name><given-names>S. L.</given-names>
<surname>Salzberg</surname></string-name></person-group>, 
<article-title>Fast gapped-read alignment with Bowtie 2</article-title>. <source>Nat. Methods</source>
<volume>9</volume>, 
<fpage>357</fpage>&#x02013;<lpage>359</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22388286</pub-id>
</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Tarasov</surname></string-name>, <string-name><given-names>A. J.</given-names>
<surname>Vilella</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Cuppen</surname></string-name>, <string-name><given-names>I. J.</given-names>
<surname>Nijman</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Prins</surname></string-name></person-group>, 
<article-title>Sambamba: Fast processing of NGS alignment formats</article-title>. <source>Bioinformatics</source>
<volume>31</volume>, 
<fpage>2032</fpage>&#x02013;<lpage>2034</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25697820</pub-id>
</mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>Li</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Handsaker</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Wysoker</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Fennell</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Ruan</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Homer</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Marth</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Abecasis</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Durbin</surname></string-name>, <collab>1000 Genome Project Data Processing Subgroup</collab></person-group>, 
<article-title>The sequence alignment/map format and SAMtools</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, 
<fpage>2078</fpage>&#x02013;<lpage>2079</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19505943</pub-id>
</mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Scheffler</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Halpern</surname></string-name>, <string-name><given-names>M. A.</given-names>
<surname>Bekritsky</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Noh</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>K&#x000e4;llberg</surname></string-name>, <string-name><given-names>X.</given-names>
<surname>Chen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Kim</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Beyter</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Krusche</surname></string-name>, <string-name><given-names>C. T.</given-names>
<surname>Saunders</surname></string-name></person-group>, 
<article-title>Strelka2: Fast and accurate calling of germline and somatic variants</article-title>. <source>Nat. Methods</source>
<volume>15</volume>, 
<fpage>591</fpage>&#x02013;<lpage>594</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30013048</pub-id>
</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. R.</given-names>
<surname>Quinlan</surname></string-name>, <string-name><given-names>I. M.</given-names>
<surname>Hall</surname></string-name></person-group>, 
<article-title>BEDTools: A flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics</source>
<volume>26</volume>, 
<fpage>841</fpage>&#x02013;<lpage>842</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20110278</pub-id>
</mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. Z.</given-names>
<surname>Johansen</surname></string-name>, <string-name><given-names>S. I.</given-names>
<surname>Novitski</surname></string-name>, <string-name><given-names>J. X.</given-names>
<surname>Hjaltelin</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Theile</surname></string-name>, <string-name><given-names>M. K.</given-names>
<surname>Boisen</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Brunak</surname></string-name>, <string-name><given-names>D. H.</given-names>
<surname>Madsen</surname></string-name>, <string-name><given-names>D. L.</given-names>
<surname>Nielsen</surname></string-name>, <string-name><given-names>I. M.</given-names>
<surname>Chen</surname></string-name></person-group>, 
<article-title>Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy</article-title>. <source>Front. Immunol.</source>
<volume>14</volume>, 
<fpage>1228907</fpage> (<year>2023</year>).<pub-id pub-id-type="pmid">37744345</pub-id>
</mixed-citation></ref></ref-list></back></article>